

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## **Cohort profile: Helping Ourselves, Helping Others - The Young Women's Breast Cancer Study (YWS): A multi-site prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 and younger**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-081157
Article Type:	Cohort profile
Date Submitted by the Author:	30-Oct-2023
Complete List of Authors:	Rosenberg, Shoshana M. ; Dana-Farber Cancer Institute; Weill Cornell Medicine Zheng, Yue; Dana-Farber Cancer Institute Ruddy, Kathryn; Mayo Clinic Poorvu, Philip D.; Dana-Farber Cancer Institute, Medical Oncology Snow, Craig; Dana-Farber Cancer Institute, Medical Oncology Kirkner, Gregory J.; Dana-Farber Cancer Institute, Medical Oncology Meyer, Meghan E.; Dana-Farber Cancer Institute, Medical Oncology Tamimi, Rulla M. ; Weill Cornell Medical College, Schapira, Lidia; Stanford University Peppercorn, Jeffrey; Massachusetts General Hospital Come, Steven; Beth Israel Deaconess Medical Center Borges, Virginia; University of Colorado Denver Warner, Ellen; Sunnybrook Health Sciences Centre, Medical Oncology Gelber, Shari; Dana-Farber Cancer Institute, Medical Oncology Collins, Laura; Beth Israel Deaconess Medical Center, Pathology Winer, Eric P.; Dana-Farber Cancer Institute, Medical Oncology Partridge, Ann; Dana-Farber Cancer Institute, Medical Oncology
Keywords:	ONCOLOGY, Breast tumours < ONCOLOGY, Quality of Life

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Cohort profile: Helping Ourselves, Helping Others - The Young Women's Breast Cancer Study**  
4  
5 **(YWS): A multi-site prospective cohort study to advance the understanding of breast cancer**  
6  
7 **diagnosed in women aged 40 and younger**  
8  
9

10  
11 Shoshana M. Rosenberg,<sup>1,2,3</sup> Yue Zheng,<sup>4</sup> Kathryn J. Ruddy,<sup>5</sup> Philip D. Poorvu,<sup>2,3</sup> Craig Snow,<sup>2,3</sup>  
12  
13 Gregory J. Kirkner,<sup>2,3</sup> Meghan E. Meyer,<sup>2,3</sup> Rulla M. Tamimi,<sup>1</sup> Lidia Schapira,<sup>6</sup> Jeffrey Peppercorn,<sup>7</sup>  
14  
15 Steven Come,<sup>8</sup> Virginia F. Borges,<sup>9</sup> Ellen Warner,<sup>10</sup> Shari Gelber,<sup>2,3</sup> Laura C. Collins,<sup>11</sup> Eric P.  
16  
17 Winer,<sup>2,3,12</sup> and Ann H. Partridge<sup>2,3</sup>  
18  
19

20  
21  
22  
23 <sup>1</sup>Population Health Sciences, Weill Cornell Medicine, New York, NY, USA (current affiliation); <sup>2</sup>Medical  
24  
25 Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; <sup>3</sup>Breast Oncology Program, Dana-Farber  
26  
27 Brigham Cancer Center, Boston, MA, USA; <sup>4</sup>Data Science, Dana-Farber Cancer Institute, Boston, MA,  
28  
29 USA; <sup>5</sup>Medical Oncology, Mayo Clinic, Rochester, MN, USA; <sup>6</sup>Department of Medicine, Division of  
30  
31 Medical Oncology, Stanford University, Stanford, CA, USA; <sup>7</sup>Department of Medicine, Division of Medical  
32  
33 Oncology, Massachusetts General Hospital, Boston MA, USA; <sup>8</sup>Medical Oncology, Beth Israel  
34  
35 Deaconess Medical Center, Boston, MA, USA; <sup>9</sup>Medical Oncology, University of Colorado Anschutz  
36  
37 Medical Campus, Aurora, CO, USA; <sup>10</sup>Department of Medicine, Division of Medical Oncology, Odette  
38  
39 Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; <sup>11</sup>Pathology, Beth Israel  
40  
41 Deaconess Medical Center, Boston, MA, USA; <sup>12</sup>Yale Cancer Center, New Haven, CT, USA (current  
42  
43 affiliation)  
44  
45

46  
47 **Corresponding author:**  
48

49  
50 Ann H. Partridge

51  
52 Dana-Farber Cancer Institute

53  
54 450 Brookline Avenue  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Boston, MA 02067

Tel: 617-632-3800

Email: [ann\\_partridge@dfci.harvard.edu](mailto:ann_partridge@dfci.harvard.edu)

**Word count:** 3790

**Figures:** 2

**Tables:** 3

**Supplemental tables:** 2

**Keywords:** young women; breast cancer; outcomes; cohort study

For peer review only

## **Abstract**

**Purpose:** Compared to older women diagnosed with breast cancer, younger women are more likely to die of breast cancer and more likely to suffer psychosocially in both the short and long-term. The Young Women's Breast Cancer Study (YWS) is a multisite prospective cohort study established to address gaps in our knowledge about this vulnerable and understudied population.

**Participants:** The YWS enrolled 1,302 women newly diagnosed with stage 0-IV breast cancer at age 40 years or younger at 13 academic and community sites in North America between 2006 and 2016. Longitudinal patient-reported outcome data are complemented by clinical data abstraction and biospecimen collection at multiple time-points.

**Findings to Date:** Key findings related to fertility include that nearly 40% of participants were interested in pregnancy following diagnosis; of those who reported interest, 10% pursued fertility preservation. Overall, approximately 10% of YWS participants became pregnant in the first 5 years after diagnosis; follow-up is ongoing for pregnancies after 5 years. Studies focused on psychosocial outcomes have characterized quality of life, post-traumatic stress, and fear of recurrence, with findings detailing the factors associated with the substantial psychosocial burden many young women face during and following active treatment. Multiple studies have leveraged YWS biospecimens, including whole exome sequencing of tumor analyses that revealed that select somatic alterations occur at different frequencies in young (age <35) versus older women with luminal A breast cancer, and a study that explored clonal hematopoiesis of indeterminate potential found it to be rare in young survivors.

**Future Plans:** With a median follow-up of approximately 10 years, the cohort is just maturing for many relevant long-term outcomes and provides outstanding opportunities to further study and build collaborations to address gaps in our knowledge, with the ultimate objective to improve care and outcomes for young women with breast cancer.

**Registration:** [clinicaltrials.gov, NCT01468246](https://clinicaltrials.gov/ct2/show/study/NCT01468246)

### **Strengths and Limitations**

- The Young Women's Breast Cancer Study (YWS) is the first and one of the largest, multi-site, prospective cohorts of women with young onset breast cancer designed to conduct regular medical record review and collect biospecimens and patient-reported outcomes.
- From 2006-2016, the YWS enrolled 1,302 women diagnosed with breast cancer at age 40 years and younger from 13 North American academic and community sites, with planned follow-up of participants up to at least 20 years post-diagnosis.
- High participant engagement (the average survey completion rate is 86%) has facilitated extended follow-up to investigate a diverse range of survivorship issues and outcomes.
- Medical record review has been completed for 100% of participants through 18 months post-diagnosis and we have collected  $\geq 1$  blood sample on 92%, and centrally reviewed primary tumor pathology on 97%, with blocks archived on 84% and tissue microarrays created on 89% of those reviewed.
- While women were recruited via systematic approaches from community and academic sites in North America, participants enrolled in the YWS are predominantly white, non-Hispanic, and highly educated, which may impact generalizability of findings to young breast cancer survivors from more diverse racial, ethnic, and socio-economic backgrounds.

## Introduction

Greater than 14,000 women aged 40 years and younger are diagnosed with breast cancer annually in the United States alone, with thousands more worldwide. Far less is known, however, about breast cancer in younger vs. older women. Further, recent population-based data have demonstrated that the incidence of breast cancer is growing in this population.<sup>1,2</sup> Breast cancer is the leading cause of cancer-related deaths in women under 40 years of age, and while improved over time, survival rates for young women with breast cancer remain lower compared to older women.<sup>3,4</sup> The reasons for the poorer outcomes experienced by young women as understood to date are complex and multifactorial.

Compared to older women, young women are more likely to present with symptoms and at a more advanced stage, due in part to diagnostic delays and lack of screening in this population.<sup>5,6</sup> Breast cancers arising in young women tend to have more unfavorable pathologic features and aggressive subtypes, including greater proportions with luminal B, HER2-positive, or triple-negative disease.<sup>7,8</sup>

Young women are at high risk of non-adherence to risk reducing adjuvant hormonal therapy.<sup>9-11</sup>

Compounding their disparate disease outcomes, young breast cancer survivors may be at greater risk of long-term or late morbidity given the aggressive therapy that they usually receive and anticipated long life trajectory in survivorship, although there are limited data in this area.

Of particular significance are the variety of young age-related medical and psychosocial issues that this population faces as a result of their diagnosis and treatment, which contribute to a greater risk of psychosocial distress compared to older patients.<sup>12</sup> These issues include hereditary predisposition and risks of future cancer, sexual dysfunction, infertility, premature menopause, body image concerns, role functioning including parenting, career and schooling disruption and the development of short- and long-term comorbidities. Collectively, these problems may influence treatment decisions, as well as disease and psychosocial outcomes.



### ***Purpose of the Young Women's Breast Cancer Study***

Young women are underrepresented in large prospective cohorts as well as in randomized trials evaluating novel therapies and prognostic tools to guide breast cancer treatment decisions.<sup>13-15</sup> Hesitancy to extrapolate data from studies of primarily older populations may result in young women being excluded or delayed in benefits from treatment improvements, or put at risk for overtreatment based solely on young age. Even in large prospective cohort studies and clinical trials inclusive of premenopausal women, as well as in population-based registries, there are rarely enough young women and/or adequate granularity of data to draw meaningful conclusions for this subpopulation. For example, the Nurses' Health Studies have previously reported 374 incident cases age <40 years (vs. 2,533 cases in women age ≥40),<sup>16</sup> the Black Women's Health Study had 529 cases of breast cancer diagnosed at age <45 years documented through 2013 (vs. 1,534 cases in women aged 45 and older),<sup>17</sup> and the Suppression of Ovarian Function Trial had 933 participants age <40 years at diagnosis,<sup>18</sup> with limited details in follow-up for most. The Young Women's Breast Cancer Study (YWS) was designed to address gaps in knowledge regarding breast cancer in younger women, including unanswered questions pertaining to diagnosis and presentation, underlying disease biology, optimal treatment, survivorship, psychosocial issues, and living with metastatic disease. The YWS is the first and one of the largest cohorts of women with young onset breast cancer designed to conduct regular medical record review and collect biospecimens and patient-reported outcomes (PROs) (**Figure 1**). The original study objectives were to 1) enroll a cohort of women age ≤40 years newly diagnosed with breast cancer; 2) characterize the cohort at diagnosis and in follow-up regarding disease and psychosocial outcomes; and 3) archive tumor and blood specimens for future studies.

### **Cohort Description**

#### ***Overview***

From 2006-2016, the YWS enrolled 1,302 women from 13 North American academic and community sites (**Supplemental Table 1**). There was high accrual of those approached for enrollment

1  
2  
3 (1302/2186, 60% participate rate). Four patients were determined to be ineligible, and one withdrew  
4 consent following enrollment leaving 1,297 women who are followed. Reasons for non-participation are  
5 detailed in **Figure 2**. The YWS is approved by the Institutional Review Board at Dana-Farber Harvard  
6 Cancer Center (DF/HCC) and other participating sites.  
7  
8  
9  
10

### 11 12 **Enrollment procedures**

13  
14 At Massachusetts sites, potentially eligible participants were systematically identified by  
15 pathology review or by pathology or clinic list review by a research nurse on a monthly or bi-monthly  
16 basis. The Dana-Farber Cancer Institute (DFCI) Survey and Data Management Core then reviewed the  
17 medical record to confirm eligibility. At sites outside of Massachusetts, study staff assisted with  
18 recruitment via systematic review of patient lists. Eligibility was confirmed prior to inviting. Inclusion  
19 criteria included: 1) female; 2) a new diagnosis of stage 0-IV breast cancer 3) age  $\leq 40$  years at  
20 diagnosis; and 4) ability to understand written and spoken English to the extent necessary to complete  
21 the questionnaires. Participants enrolled a median of 4 (range: 0-29) months following diagnosis.  
22 Following receipt of written informed consent, participants were mailed a welcome letter, medical record  
23 release form, tumor specimen request form, and the baseline survey. Current median follow-up of the  
24 cohort is 10 years (range: 0.4-16 years).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 **Participant characteristics**

40  
41 **Table 1** includes a summary of YWS participant age at diagnosis, race, and ethnicity. Baseline  
42 survey questions asked participants about their race and ethnicity. For baseline survey non-responders  
43 or instances where this information was not reported, race/ethnicity as determined from medical record  
44 at screening/enrollment was used. Approximately 14% of YWS participants are from a non-White  
45 and/or Hispanic racial/ethnic background. Median age at diagnosis was 36 (range: 17-40) years. Key  
46 cancer information including stage, grade, subtype, and BRCA mutation status is detailed in **Table 2**.  
47 Recognizing that there have been changes in how we measure social determinants of health since the  
48 baseline survey was developed and to make these data more complete, we are sending YWS  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 participants a supplemental survey including updated questions regarding race, ethnicity, gender, and  
4  
5 sexual identity.  
6

### 7 ***Patient and Public Involvement***

8  
9  
10 Since the study's inception, we have invited patient volunteers and patient advocates to review  
11  
12 survey content as well as assist with strategies to communicate results to YWS participants and other  
13  
14 young patients. We routinely share lay summary results from YWS analyses directly through the DFCI  
15  
16 Program for Young Adults with Breast Cancer newsletter as well as intermittent webinars and patient  
17  
18 forums. Newsletters and webinars are also archived on the program's public website  
19  
20 (<https://youngandstrong.dana-farber.org>).  
21  
22

### 23 ***YWS Data Collection and Follow-up***

24  
25  
26 *Surveys:* Participants completed surveys at study baseline (median of 5 months post-diagnosis), 6  
27  
28 months after enrollment, and 1-year post-diagnosis. Participants were then surveyed every 6 months  
29  
30 through 3 years, and annually thereafter. Participants enrolled at the Toronto site (N=62) are sent  
31  
32 abbreviated ("short-form") surveys that ask for socio-demographics, how their breast cancer presented,  
33  
34 fertility and gynecologic information, and cancer endpoints. At the 10-year timepoint, Toronto  
35  
36 participants are sent a full survey to complete. A smaller subset of participants (N=29) who enrolled at  
37  
38 other sites chose to complete the short-form follow-up annual surveys that only ask about fertility,  
39  
40 gynecologic and cancer outcomes. For the initial 7 years of the YWS, all surveys were mailed to main  
41  
42 study participants; participants completing short-form surveys were given the option of completing  
43  
44 surveys on paper or online via Survey Monkey. Beginning at the 8-year survey time point, participants  
45  
46 were offered the option to complete an electronic survey through REDCap. In March 2020, due to  
47  
48 COVID restrictions limiting the ability to mail materials, participants with a valid email address (98%)  
49  
50 were sent surveys through REDCap. Collectively, these surveys have yielded an unparalleled resource  
51  
52 of longitudinal PRO data related to menopausal status, fertility, anxiety, depression, quality of life  
53  
54 (QOL), fear of recurrence, treatment side-effects, employment, genetics, and treatment decision-  
55  
56  
57  
58  
59  
60

1  
2  
3 making (see **Table 3** for domains/timeline for the first 15 years of follow-up). We also periodically invite  
4 participant subsets to complete supplemental surveys to investigate salient issues in greater detail.<sup>19-24</sup>

5  
6  
7 *Follow-up to optimize survey response rates:* A research coordinator systematically contacts  
8 participants who do not complete their surveys with a phone call at 3 weeks after the initial survey is  
9 sent out; the survey is re-sent at 6 weeks if the participant has still not completed the survey at that  
10 timepoint. Additional calls and/or survey resends are then conducted monthly up to 6 months following  
11 the initial send out, as needed. Response rates (surveys received/surveys sent) for the majority of  
12 survey time points range from 86%-91%. Response rates for 7 and 10-year surveys are modestly lower  
13 (71% for 7-year and 65% for 10-year) due to our attempt to re-engage non-responding participants at  
14 those timepoints.  
15  
16  
17  
18  
19  
20  
21  
22  
23

24  
25 *Medical Records:* Medical records through the first 18 months following diagnosis are available for  
26 100% of participants. Records are also reviewed at additional timepoints (including at 10 years) to 1)  
27 confirm and collect specifics on cancer outcomes (recurrences, new primary breast cancers, other  
28 cancers) that are self-reported on surveys; and 2) to update comorbidities including recurrences and  
29 new cancers and vital status among participants who do not regularly complete surveys. We have  
30 abstracted initial treatment information, including specific chemotherapy regimens started and received,  
31 surgery, radiation, genetic testing (panel type and results), and co-morbidities using the Charlson  
32 framework<sup>25,26</sup> from the medical record to validate/supplement what patients report on surveys, and to  
33 fill in missing data.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44  
45 *Ascertainment of Cancer Outcomes and Vital Status:* Recurrences, new primary breast cancers, and  
46 new (non-breast) cancers are assessed on each survey. In addition to site(s) of recurrence or new  
47 cancer, participants are asked to report the date of the recurrence. Any self-report of a recurrence or  
48 new cancer, including site and date (either radiologic or pathologic confirmation) is confirmed by  
49 medical record review. Because this process relies on survey responses to ascertain outcomes, for  
50 those participants who are no longer responding to surveys we request and review updated medical  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 records for these patients every 4 years. For participants treated at DFCI, Brigham and Women's  
4 Hospital, Massachusetts General Hospital or an affiliate network site, the National Death Index is  
5 queried periodically to obtain vital status information. Following the 2018-2019 update, we were able to  
6 ascertain oncologic outcomes and vital status for 321 patients who were survey non-responders. As of  
7 September 2023, among the entire cohort, we have documented 181 participants with distant  
8 metastatic recurrences, 96 participants with locoregional recurrences, 22 participants with new primary  
9 breast cancers, and 49 participants with new non-breast primary cancers, and 186 deaths.

10  
11  
12  
13  
14  
15  
16  
17  
18 *Tissue Specimen Collection/Storage:* Pathology reports, hematoxylin and eosin (H&E) stained slides,  
19 and a representative paraffin block of tumor were requested from the institution where the patient had  
20 her surgery; the patient's signed release for the specimens and reports were sent to the pathology  
21 department. A YWS study pathologist reviewed each pathology report and an H&E stained section of  
22 the tumor block to annotate tumor details.<sup>8,27</sup> Slides from the core needle biopsy were requested as well  
23 as from the surgery in neoadjuvant therapy cases. Hormone and HER-2/neu (HER2) receptor  
24 expression, and lymph node status, were extracted from the pathology reports. Of 1297 participants  
25 followed, 1278 (99%) consented to providing a tumor specimen for review. Primary tumor pathology  
26 has been centrally reviewed on 97% of patients (1242/1278), with blocks (N=1120) and cores for the  
27 tissue microarray (N=21) from tumor specimens collected on 1141 patients (88%). Currently, there are  
28 1370 specimens from 1242 patients available in the tissue microarray blocks (patients who received  
29 neoadjuvant therapy may have more than one block).

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44 *Blood Collection/Storage:* Blood is collected at three timepoints (two 10mL tubes of whole blood at  
45 each timepoint), each with a several month "window" to maximize our ability to collect blood while  
46 minimizing burden: baseline (enrollment up to 9 months post-diagnosis); 1-year (9 months-2 years  
47 post-diagnosis); and 4-year (3.5 – 5 years post diagnosis). Overall, 94% (1224/1297) of participants  
48 consented to blood collection. Of these, there is at least one sample available from 92% of participants,  
49 with 73% of participants providing samples at two or more time points (**Supplemental Table 2**).

1  
2  
3 Women were asked to go to their treating institution or a local laboratory with the materials provided in  
4 the blood specimen kit, unless drawn at DFCI where kits are provided on site by staff. Specimens were  
5 processed at the DFCI Breast Cancer CORE Blood Repository, where whole blood (4 aliquots/2ml  
6 each) and plasma (2 aliquots/2mL each) were isolated and banked for future studies.  
7  
8  
9  
10

### 11 **Findings to Date**

12  
13  
14 Since its inception, YWS investigations have characterized more fully the experience of breast  
15 cancer in young women, creating a platform from which to study molecular and biologic issues, as well  
16 as the health and psychosocial repercussions of a breast cancer diagnosis and treatment at a young  
17 age. As the YWS has matured, we have expanded our investigations to include collaborations with  
18 basic and translational scientists enabling us to address new questions, advancing knowledge of the  
19 biology of the disease as well as to improve clinical care and outcomes. In addition, research findings  
20 from the YWS have informed international guidelines and clinical practice.<sup>28,29</sup>  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 ***Fertility Issues and Pregnancy***

31  
32 In 2014, we published findings from the baseline survey regarding fertility concerns and fertility  
33 preservation strategies used.<sup>30</sup> Since then, additional publications from the YWS have described breast  
34 cancer diagnosed during pregnancy,<sup>31</sup> pregnancy after breast cancer,<sup>32</sup> treatment-related  
35 amenorrhea,<sup>33</sup> fertility concerns and endocrine therapy decision-making,<sup>34</sup> and fertility concerns in  
36 germline genetic carriers.<sup>35</sup> Key findings included the observation that nearly 40% of participants were  
37 interested in pregnancy after breast cancer; of those interested, 10% pursued fertility preservation  
38 strategies.<sup>30</sup> Another study documented that approximately 20% of women become amenorrheic in  
39 survivorship after standard chemotherapy, with variability by chemotherapy type and age.<sup>33</sup> A third  
40 study evaluated post-diagnosis pregnancies, observing that 10% became pregnant in the first 5 years  
41 after breast cancer.<sup>32</sup> Fertility outcomes remain a primary outcome of interest in continued follow-up of  
42 the cohort and the rich and detailed fertility and gynecologic data collected at each time point will allow  
43 for novel and detailed investigations regarding impact of pregnancy on cancer endpoints, and  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 menopausal and related comorbidity outcomes. Findings from this work have been referenced in  
4 international guidelines<sup>28,29</sup> and informed an international trial that evaluated the safety of pregnancy  
5 after breast cancer.<sup>36</sup> We are also participating in an international, multi-site, retrospective cohort study  
6 (PI: Dr. Matteo Lambertini, University of Genoa, IT) inclusive of >1400 patients with BRCA+ breast  
7 cancer from 30 sites across North America, Europe, Latin America, and Israel, contributing clinical,  
8 genetic, and PRO data on 125 YWS participants with BRCA mutations. To date, there have been two  
9 major publications reporting analyses of pregnancy outcomes as well as clinical outcomes from this  
10 collaboration.<sup>37,38</sup>

### 21 ***Systemic Treatment and Disease Recurrence and Response***

22  
23 In 2017, we conducted a study examining the prognostic value of genomic expression prediction  
24 assays in the YWS. Prior research that led to the routine incorporation of such tools into clinical care  
25 had included relatively few women <40 years old, resulting in hesitation among providers to use them  
26 for young women. We demonstrated that Recurrence Score (RS) was prognostic and appeared to be  
27 predictive of chemotherapy benefit or lack thereof in patients with node-negative disease.<sup>39</sup> These data  
28 have informed recent guidelines and clinical practice supporting the use of RS in young patients to  
29 influence chemotherapy decisions.<sup>28</sup> We subsequently demonstrated the association of RS with  
30 pathologic complete response (pCR) after neoadjuvant chemotherapy for hormone receptor-positive  
31 disease<sup>40</sup>; results from this study are providing preliminary data for planned correlative work in a pre-  
32 operative clinical trial in the Alliance for Clinical Trials in Oncology.

### 45 ***Psychosocial Implications of Breast Cancer in Young Women***

46  
47 A large focus of the YWS has been to study the early psychological and social repercussions of  
48 breast cancer in young women to identify areas for tailored support and management strategies. We  
49 have characterized sexual functioning and body image issues, the impact of a diagnosis on  
50 employment, post-traumatic stress, fear of recurrence, anxiety and depression in women with de novo  
51 stage IV disease, as well as the impact of the diagnosis on the partners of YWS participants.<sup>41-48</sup>

1  
2  
3 Recent studies have found that more extensive surgery and radiation are associated with poorer  
4 QOL<sup>21,49</sup> as well as increased arm morbidity.<sup>50</sup> Collectively, our findings indicate that young women  
5 experience a substantial psychosocial burden during and following the completion of active treatment,  
6 and this burden is associated with certain patient, disease and treatment variables which can be  
7 targeted for intervention.  
8  
9  
10  
11  
12

### 13 ***Biological Differences in Breast Cancer by Age***

14 Collaborative efforts have yielded important findings to date including a comparison of whole  
15 exome sequencing profiles of the youngest 100 participants ( $\leq 35$  years at diagnosis) to older women  
16 from The Cancer Genome Atlas (TCGA).<sup>51,52</sup> This analysis revealed that somatic alterations in three  
17 genes (*PIK3CA*, *GATA3*, and *ARID1A*) occur at different frequencies in young versus older women with  
18 luminal A breast cancer.<sup>52</sup> Additional investigation of these genes could delineate biological  
19 susceptibilities for young patients. Several additional studies have used or pooled tissue and/or blood  
20 specimens including a genome wide association study characterizing single nucleotide polymorphisms  
21 in young patients,<sup>53</sup> a study of RasGAP genes in luminal B tumors,<sup>54</sup> and a study of somatic mutations  
22 in patients with metastatic triple negative breast cancer,<sup>55</sup> and the development of a test to identify  
23 minimal residual disease in early-stage breast cancer.<sup>51</sup> Most recently, we used novel DNA sequencing  
24 methods to evaluate the prevalence and mutation spectrum of clonal hematopoiesis in young women  
25 and its association with patient and treatment characteristics and outcomes.<sup>56</sup> Reassuringly, clonal  
26 hematopoiesis of indeterminate potential (CHIP) was rare, with a prevalence of  $< 3\%$  among the 878  
27 women in the analytic cohort.<sup>56</sup> The YWS has also provided clinical data detailing cancer outcomes of  
28 nulliparous vs. recently parous women, for an analysis supporting the novel pre-clinical finding that  
29 weaning-induced liver involution establishes a pro-metastatic microenvironment, a potential explanation  
30 for more poor cancer outcomes of recently parous women.<sup>57</sup> Several analyses to understand the  
31 biologic underpinnings of early onset breast cancer are underway.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### **Collaboration**

The YWS is uniquely positioned for investigations of age-related tumor and host biology as well as studies evaluating the impact of hereditary predisposition, post-diagnosis pregnancy, premature menopause, psychosocial, lifestyle and care delivery on cancer endpoints and comorbidities. The YWS research team includes medical, surgical, and radiation oncologists, epidemiologists, pathologists, and biostatisticians, and our collaborations have grown to include experts in cancer genomics, biology, tumor microenvironment, and behavioral health. While data are not publicly available, investigators interested in accessing YWS-generated data and/or biospecimens should contact the Principal Investigator (A. Partridge) and submit a request to the DF/HCC breast users committee (<https://www.dfhcc.harvard.edu/research/research-programs/clinical-based-programs/breast-cancer/program-resources/dfhcc-breast-users-committee/>).

### **Future Directions**

The YWS has proven to be a rich scientific resource that has resulted in impactful research that has advanced our understanding of breast cancer in young women, generated new lines of investigation, and informed clinical guidelines. Breast cancer is the leading cause of cancer-related deaths in young women, and while improved over time, survival rates for young women with breast cancer remain lower compared to older women.<sup>3,4</sup> Thus, identifying risk factors for these poorer outcomes in younger women is critical. With the cohort maturing, we expect the number of recurrent disease events expected to increase by ~50% over the next 5 years and beyond, allowing for further evaluation of predictors of oncologic outcomes, including breast cancer free survival and overall survival. With relatively large numbers of young patients treated with contemporary regimens and well-annotated treatment details, we will be well-positioned to evaluate the impact of post-diagnosis pregnancies on recurrence, new primary cancer, or death, assessment of risk factors for second cancers by breast cancer phenotype and germline pathogenic variant status, as well as risk factors for late recurrences among women diagnosed at a young age. Studies of the role of ctDNA on predicting

1  
2  
3 late recurrence and exploring tumor and host characteristics that may be conducive to  
4 recurrence/disease resistance to therapy in young women (e.g., tumor immune microenvironment  
5 differences by recent parity status at diagnosis) have great potential.  
6  
7  
8

9  
10 As a survivorship cohort, evaluating long-term, late effects of breast cancer treatment and  
11 survivorship is a central objective of the YWS. A critical charge of cancer survivorship research is  
12 identifying potentially modifiable factors that predict these risks. Young breast cancer survivors may be  
13 at high risk of long-term or late morbidity given the aggressive therapy they usually receive and  
14 anticipated long life trajectory after the cancer. Additionally, they may have hereditary, behavioral, and  
15 comorbidity predispositions to disease. The concerns unique to or accentuated by their stage of life at  
16 diagnosis also appear to contribute to the increased risk of psychological distress seen in this age  
17 group both at diagnosis and in long-term follow-up.<sup>12</sup> With a median follow-up of 10 years, we are now  
18 well-poised to study late and long-term morbidity, including premature menopause (age <45 years),  
19 which in non-cancer populations is associated with substantial multimorbidity including increased risk of  
20 depression, hyperlipidemia, heart disease, asthma, chronic obstructive pulmonary disease, arthritis and  
21 osteoporosis.<sup>58</sup> On each survey, YWS participants are asked about their menstrual status, including  
22 date of last menstrual period, reasons for periods stopping, as well as questions about gynecologic  
23 procedures providing granular data to inform analyses. Given the current age of the cohort, the next  
24 several years are a critical time to conduct in-depth assessment of the menopausal transition among  
25 women who remained premenopausal following treatment, including timing, risk factors for premature  
26 menopause, and the impact of early menopause on QOL and comorbidities in this population. This data  
27 resource will also facilitate investigations ranging from health care utilization assessments, changes in  
28 lifestyle factors over time, and trajectories of QOL, to evaluations of the association of specific co-  
29 morbidities (e.g., heart disease, diabetes) with premature menopause, weight gain, body composition,  
30 metabolic biomarkers, inflammatory mediators, hormone levels, and biomarkers of accelerated aging.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Strengths and Limitations**

With a repository of biospecimens, clinical data, and serial PRO collection, the YWS is a robust platform from which to study molecular and biologic issues, as well as the health and psychosocial repercussions of a breast cancer diagnosis and treatment in young women. One of the core strengths of the YWS is high participant engagement, which has facilitated our ability to follow participants for both medical and psychosocial outcomes in extended follow-up. Additionally, we have leveraged the collection of blood specimens at three time points – baseline, 1 year, and 4 years after diagnosis – for novel investigations that are complemented with clinical data that have been systematically abstracted from the medical record. However, as the YWS is an observational cohort study, establishing causality vs. association can be challenging and there is a risk of unmeasured or unaccounted for confounders in analyses. Additionally, while the YWS is a multi-site study that included both academic and community sites, women enrolled in the YWS are predominantly white, non-Hispanic, and highly educated, which may impact generalizability of findings to young breast cancer survivors from more diverse racial, ethnic, and socio-economic backgrounds. Acknowledging this limitation, more recent studies conducted by our team, including intervention trials informed by YWS findings, have focused efforts to improve outreach to patients from historically under-represented racial and ethnic groups.

1  
2  
3 **Data availability statement:** Requests to access YWS data/biospecimens should be made to the  
4  
5 Principal Investigator, Dr. Ann Partridge ([ann\\_partridge@dfci.harvard.edu](mailto:ann_partridge@dfci.harvard.edu)).

6  
7 **Acknowledgements:** We thank all participants for their past and continued contributions to the YWS  
8  
9 study. We also thank Ms. Kate Bifolck for editorial and submission assistance; she is a full-time  
10  
11 employee of Dana-Farber Cancer Institute.

12  
13  
14 **Funding:** Susan G. Komen and Breast Cancer Research Foundation

15  
16 **Ethics statements:** The YWS is approved by the Institutional Review Board at Dana-Farber Harvard  
17  
18 Cancer Center (IRB# 06-169) and other participating sites. Participants provided written informed  
19  
20 consent at the time of enrollment.

21  
22  
23 **Competing Interests:** SMR reports grant funding from Conquer Cancer/Pfizer. VB reports research  
24  
25 funding (paid to institution) from SeaGen, AstraZeneca, Gilead, and Olema; consultation for SeaGen,  
26  
27 AstraZeneca, Lilly, Gilead, and Olema; and stock/founder of PEARL Scientific. AHP reports royalties  
28  
29 from Wolters Kluwer (paid to self) for authorship of UpToDate. All remaining authors have no  
30  
31 disclosures to report.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Ellington TD, Miller JW, Henley SJ, et al: Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age Among Women Aged  $\geq 20$  Years - United States, 1999-2018. *MMWR Morb Mortal Wkly Rep* 71:43-47, 2022
2. Miller KD, Fidler-Benaoudia M, Keegan TH, et al: Cancer statistics for adolescents and young adults, 2020. *CA Cancer J Clin* 70:443-459, 2020
3. Guo F, Kuo Y-f, Shih YCT, et al: Trends in breast cancer mortality by stage at diagnosis among young women in the United States. *Cancer* 124:3500-3509, 2018
4. Kim HJ, Kim S, Freedman RA, et al: The impact of young age at diagnosis (age  $< 40$  years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. *The Breast* 61:77-83, 2022
5. Partridge AH, Hughes ME, Ottesen RA, et al: The effect of age on delay in diagnosis and stage of breast cancer. *Oncologist* 17:775-82, 2012
6. Zabicki K, Colbert JA, Dominguez FJ, et al: Breast cancer diagnosis in women  $\leq 40$  versus 50 to 60 years: increasing size and stage disparity compared with older women over time. *Ann Surg Oncol* 13:1072-7, 2006
7. Azim HA, Jr., Partridge AH: Biology of breast cancer in young women. *Breast Cancer Res* 16:427, 2014
8. Guzman-Arocho YD, Rosenberg SM, Garber JE, et al: Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. *Br J Cancer* 126:302-309, 2022
9. Hershman DL, Shao T, Kushi LH, et al: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. *Breast Cancer Res Treat* 126:529-37, 2011
10. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. *J Clin Oncol* 21:602-6, 2003
11. Hershman DL, Kushi LH, Shao T, et al: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. *J Clin Oncol* 28:4120-8, 2010
12. Howard-Anderson J, Ganz PA, Bower JE, et al: Quality of Life, Fertility Concerns, and Behavioral Health Outcomes in Younger Breast Cancer Survivors: A Systematic Review. *J Natl Cancer Inst*, 2012

13. Cardoso F, van't Veer LJ, Bogaerts J, et al: 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med* 375:717-29, 2016
14. Kalinsky K, Barlow WE, Gralow JR, et al: 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. *N Engl J Med* 385:2336-2347, 2021
15. Sparano JA, Gray RJ, Makower DF, et al: Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med* 373:2005-14, 2015
16. Warner ET, Colditz GA, Palmer JR, et al: Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40? *Breast Cancer Res Treat* 142:165-75, 2013
17. Bertrand KA, Bethea TN, Adams-Campbell LL, et al: Differential Patterns of Risk Factors for Early-Onset Breast Cancer by ER Status in African American Women. *Cancer Epidemiol Biomarkers Prev* 26:270-277, 2017
18. Francis PA, Pagani O, Fleming GF, et al: Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N Engl J Med* 379:122-137, 2018
19. Borstelmann NA, Gray TF, Gelber S, et al: Psychosocial issues and quality of life of parenting partners of young women with breast cancer. *Support Care Cancer*, 2022
20. Borstelmann NA, Rosenberg S, Gelber S, et al: Partners of young breast cancer survivors: a cross-sectional evaluation of psychosocial concerns, coping, and mental health. *J Psychosoc Oncol* 38:670-686, 2020
21. Dominici L, Hu J, Zheng Y, et al: Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. *JAMA Surg* 156:e213758, 2021
22. Rosenberg SM, Tracy MS, Meyer ME, et al: Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. *Ann Intern Med* 159:373-81, 2013
23. Walker HE, Rosenberg SM, Stanton AL, et al: Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer. *J Adolesc Young Adult Oncol* 5:16-23, 2016
24. Sella T, Fell GG, Miller PG, et al: Patient perspectives on testing for clonal hematopoiesis of indeterminate potential. *Blood Adv* 6:6151-6161, 2022
25. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 40:373-83, 1987

- 1  
2  
3 26. Sangha O, Stucki G, Liang MH, et al: The Self-Administered Comorbidity Questionnaire:  
4 a new method to assess comorbidity for clinical and health services research. *Arthritis Rheum* 49:156-  
5 63, 2003  
6
- 7  
8 27. Collins LC, Marotti JD, Gelber S, et al: Pathologic features and molecular phenotype by  
9 patient age in a large cohort of young women with breast cancer. *Breast Cancer Res Treat* 131:1061-6,  
10 2012  
11
- 12 28. Paluch-Shimon S, Cardoso F, Partridge AH, et al: ESO-ESMO 4th International  
13 Consensus Guidelines for Breast Cancer in Young Women (BCY4). *Ann Oncol* 31:674-696, 2020  
14
- 15  
16 29. Oktay K, Harvey BE, Partridge AH, et al: Fertility Preservation in Patients With Cancer:  
17 ASCO Clinical Practice Guideline Update. *J Clin Oncol* 36:1994-2001, 2018  
18
- 19  
20 30. Ruddy KJ, Gelber SI, Tamimi RM, et al: Prospective study of fertility concerns and  
21 preservation strategies in young women with breast cancer. *J Clin Oncol* 32:1151-6, 2014  
22
- 23  
24 31. Lee GE, Rosenberg SM, Mayer EL, et al: Contemporary management of breast cancer  
25 during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer.  
26 *Breast J* 25:1104-1110, 2019  
27
- 28 32. Poorvu PD, Gelber SI, Zheng Y, et al: Pregnancy after breast cancer: Results from a  
29 prospective cohort of young women with breast cancer. *Cancer* 127:1021-1028, 2021  
30
- 31  
32 33. Poorvu PD, Hu J, Zheng Y, et al: Treatment-related amenorrhea in a modern,  
33 prospective cohort study of young women with breast cancer. *NPJ Breast Cancer* 7:99, 2021  
34
- 35  
36 34. Sella T, Poorvu PD, Ruddy KJ, et al: Impact of fertility concerns on endocrine therapy  
37 decisions in young breast cancer survivors. *Cancer* 127:2888-2894, 2021  
38
- 39  
40 35. Lewinsohn R, Zheng Y, Rosenberg SM, et al: Fertility Preferences and Practices Among  
41 Young Women With Breast Cancer: Germline Genetic Carriers Versus Noncarriers. *Clin Breast Cancer*  
42 23:317-323, 2023  
43
- 44  
45 36. Partridge AH, Niman SM, Ruggeri M, et al: Interrupting Endocrine Therapy to Attempt  
46 Pregnancy after Breast Cancer. *N Engl J Med* 388:1645-1656, 2023  
47
- 48  
49 37. Lambertini M, Ameye L, Hamy AS, et al: Pregnancy After Breast Cancer in Patients With  
50 Germline BRCA Mutations. *J Clin Oncol* 38:3012-3023, 2020  
51
- 52  
53 38. Lambertini M, Ceppi M, Hamy AS, et al: Clinical behavior and outcomes of breast cancer  
54 in young women with germline BRCA pathogenic variants. *NPJ Breast Cancer* 7:16, 2021  
55  
56  
57  
58  
59


- 1  
2  
3 39. Poorvu PD, Gelber SI, Rosenberg SM, et al: Prognostic Impact of the 21-Gene  
4 Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-  
5 Positive/HER2-Negative Breast Cancer. *J Clin Oncol* 38:725-733, 2020  
6  
7  
8 40. Sella T, Gelber SI, Poorvu PD, et al: Response to neoadjuvant chemotherapy and the  
9 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast  
10 cancer. *Breast Cancer Res Treat* 186:157-165, 2021  
11  
12 41. Borstelmann NA, Rosenberg SM, Ruddy KJ, et al: Partner support and anxiety in young  
13 women with breast cancer. *Psychooncology* 24:1679-85, 2015  
14  
15  
16 42. Rosenberg SM, Vaz-Luis I, Gong J, et al: Employment trends in young women following  
17 a breast cancer diagnosis. *Breast Cancer Res Treat* 177:207-214, 2019  
18  
19  
20 43. Vazquez D, Rosenberg S, Gelber S, et al: Posttraumatic stress in breast cancer  
21 survivors diagnosed at a young age. *Psychooncology* 29:1312-1320, 2020  
22  
23  
24 44. Park EM, Gelber S, Rosenberg SM, et al: Anxiety and Depression in Young Women  
25 With Metastatic Breast Cancer: A Cross-Sectional Study. *Psychosomatics* 59:251-258, 2018  
26  
27 45. von Hippel C, Rosenberg SM, Austin SB, et al: Identifying distinct trajectories of change  
28 in young breast cancer survivors' sexual functioning. *Psychooncology* 28:1033-1040, 2019  
29  
30  
31 46. Rosenberg SM, Tamimi RM, Gelber S, et al: Treatment-related amenorrhea and sexual  
32 functioning in young breast cancer survivors. *Cancer* 120:2264-71, 2014  
33  
34 47. Rosenberg SM, Tamimi RM, Gelber S, et al: Body image in recently diagnosed young  
35 women with early breast cancer. *Psychooncology* 22:1849-55, 2013  
36  
37  
38 48. Schapira L, Zheng Y, Gelber SI, et al: Trajectories of fear of cancer recurrence in young  
39 breast cancer survivors. *Cancer* 128:335-343, 2022  
40  
41  
42 49. Rosenberg SM, Dominici LS, Gelber S, et al: Association of Breast Cancer Surgery With  
43 Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors. *JAMA Surg* 155:1035-  
44 1042, 2020  
45  
46 50. Kuijter A, Dominici LS, Rosenberg SM, et al: Arm Morbidity After Local Therapy for  
47 Young Breast Cancer Patients. *Ann Surg Oncol* 28:6071-6082, 2021  
48  
49  
50 51. Parsons HA, Rhoades J, Reed SC, et al: Sensitive Detection of Minimal Residual  
51 Disease in Patients Treated for Early-Stage Breast Cancer. *Clin Cancer Res* 26:2556-2564, 2020  
52  
53  
54 52. Waks AG, Kim D, Jain E, et al: Somatic and germline genomic alterations in very young  
55 women with breast cancer. *Clin Cancer Res*, 2022  
56  
57  
58  
59  
60



- 1  
2  
3 53. Rath M, Li Q, Li H, et al: Evaluation of significant genome-wide association studies risk -  
4 SNPs in young breast cancer patients. PLoS One 14:e0216997, 2019  
5  
6  
7 54. Olsen SN, Wronski A, Castano Z, et al: Loss of RasGAP Tumor Suppressors Underlies  
8 the Aggressive Nature of Luminal B Breast Cancers. Cancer Discov 7:202-217, 2017  
9  
10 55. Stover DG, Parsons HA, Ha G, et al: Association of Cell-Free DNA Tumor Fraction and  
11 Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin  
12 Oncol 36:543-553, 2018  
13  
14  
15 56. Gibson CJ, Fell G, Sella T, et al: Clonal Hematopoiesis in Young Women Treated for  
16 Breast Cancer. Clin Cancer Res 29:2551-2558, 2023  
17  
18 57. Goddard ET, Hill RC, Nemkov T, et al: The Rodent Liver Undergoes Weaning-Induced  
19 Involution and Supports Breast Cancer Metastasis. Cancer Discov 7:177-187, 2017  
20  
21  
22 58. Rocca WA, Gazzuola-Rocca L, Smith CY, et al: Accelerated Accumulation of  
23 Multimorbidity After Bilateral Oophorectomy: A Population-Based Cohort Study. Mayo Clin Proc  
24 91:1577-1589, 2016  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


Figures

Figure 1. Overview of YWS data and biospecimen collection



YWS, Young Women's Breast Cancer Study

1  
2  
3 **Figure 2. YWS Study Flow Diagram**  
4  
5  
6  
7



**Table 1. Demographic Characteristics**

	N (%)
<b>Age at diagnosis</b>	
<25	25 (2)
25-30	139 (11)
31-35	352 (27)
36-40	780 (60)
<b>Race</b>	
American Indian /Alaska Native	6 (<1)
Asian	88 (7)
Native Hawaiian/Other Pacific Islander	0 (0)
Black or African American	48 (4)
White	1101 (85)
More than one race	16 (1)
Unknown or not reported	38 (3)
<b>Ethnicity</b>	
Hispanic	56 (4)
Non-Hispanic	1045 (81)
Unknown or not reported	196 (15)

**Table 2. Disease/tumor characteristics and BRCA mutation status (N=1297)**

	N (%)
<b>Stage</b>	
0	98 (8)
I	413 (32)
II	525 (41)
III	197 (15)
IV	64 (5)
<b>Bilateral breast cancer</b>	21 (2)
<b>Tumor grade</b>	
1	89 (7)
2	445 (34)
3	752 (58)
Missing/Unknown	11 (0.9)
<b>ER status</b>	
Positive	945 (73)
Negative	351 (27)
Missing/Unknown	1 (<1)
<b>PR status</b>	
Positive	848 (65)
Negative	441 (34)
Missing/Unknown	8 (<1)
<b>HER2 status</b>	
Positive	360 (28)
Negative	880 (68)
Missing/Unknown/Not performed*	57 (4)
<b>Subtype</b>	
Luminal A-like	395 (31)
Luminal B-like	269 (21)
Luminal B/HER2	255 (20)
HER2-enriched (ER-, PR-, HER2+)	105 (8)
Triple negative	210 (16)
Missing/Unknown	63 (5)
<b>BRCA mutation status</b>	
BRCA1+	90 (7)
BRCA2+	54 (4)
Variant of unknown significance	54 (4)
No mutation detected	919 (71)
Not tested or unknown testing status	180 (14)

\*Missing/Unknown subtype includes cases of DCIS for which HER2 was not performed

**Table 3. Summary of Primary Survey Domains and Schedule, Baseline through Year 15**

	Survey Schedule																		
	Baseline	Month					Year												
		6	12	18	24	30	3	4	5	6	7	8	9	10	11	12	13	14	15
<b>Socio-demographics including insurance, finances</b>	X		X		X		X	X	X	X	X	X	X	X	X	X	X	X	X
<b>Medical/ Family History</b>	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
<b>Genetics</b>			X		X		X		X		X		X						
<b>Health-related Activities/Social History</b>	X		X		X		X	X	X	X	X	X	X						
<b>Fertility/Gynecologic</b>	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
<b>Lactation Assessment</b>	X		X		X		X		X		X		X		X		X		X
<b>Contraception</b>									X		X								
<b>QOL/Anxiety/Depression</b>	X	X	X		X		X	X	X		X			X					X
<b>Coping</b>		X		X															
<b>Fear of Recurrence</b>	X		X		X		X	X	X		X			X					X
<b>Menopausal Symptoms</b>	X	X	X		X		X	X	X		X			X					X
<b>Social Support</b>	X		X		X		X	X	X										
<b>Spirituality Assessment</b>	X						X												
<b>Treatment Decisions</b>		X																	
<b>Medications List</b>	X		X		X		X	X	X	X	X	X	X	X					X
<b>Tamoxifen Adherence</b>						X													
<b>Healthcare Utilization</b>											X								X

Peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**SUPPLEMENTAL MATERIAL**

**Cohort profile: Helping Ourselves, Helping Others - The Young Women’s Breast Cancer Study (YWS): A multi-site prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 and younger**

**Supplemental Tables: 2**

For peer review only

**Supplemental Table 1. YWS enrollment sites**

Site	State/Country	Number Enrolled
Dana-Farber Cancer Institute/Brigham and Women's Hospital <sup>a</sup>	MA	669
Beth Israel Deaconess Medical Center <sup>a</sup>	MA	50
Cape Cod Hospital <sup>b</sup>	MA	19
Faulkner Hospital <sup>a</sup>	MA	47
Lowell General Hospital <sup>b</sup>	MA	11
Massachusetts General Hospital <sup>a</sup>	MA	256
Mayo Clinic <sup>a</sup>	MN	35
Milford Hospital <sup>b</sup>	MA	1
Newton-Wellesley Hospital <sup>b</sup>	MA	30
North Shore Cancer Center (Salem) <sup>b</sup>	MA	21
South Shore Hospital <sup>b</sup>	MA	9
Sunnybrook Health Sciences <sup>a</sup>	Canada	62
University of Colorado Hospital <sup>a</sup>	CO	92

<sup>a</sup>academic sites <sup>b</sup>community sites

YWS, Young Women's Breast Cancer Study; MA, Massachusetts; MN, Minnesota; CO, Colorado



Supplemental Table 2. YWS Blood Specimens Collected

Number of Collections	Patients (N)	Baseline	1 year	4 year
1 Timepoint	N=71			
	N=137			
	N=23			
2 Timepoints	N=247			
	N=44			
	N=132			
3 Timepoints	N=471			
<b>Total/Timepoint</b>		N=833	N=987	N=670

# BMJ Open

## Cohort profile: Helping Ourselves, Helping Others - The Young Women's Breast Cancer Study (YWS): A multi-site prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 and younger

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-081157.R1
Article Type:	Cohort profile
Date Submitted by the Author:	22-Dec-2023
Complete List of Authors:	Rosenberg, Shoshana M. ; Dana-Farber Cancer Institute, Medical Oncology; Weill Cornell Medicine, Population Health Sciences Zheng, Yue; Dana-Farber Cancer Institute, Data Science Ruddy, Kathryn; Mayo Clinic, Medical Oncology Poorvu, Philip D.; Dana-Farber Cancer Institute, Medical Oncology Snow, Craig; Dana-Farber Cancer Institute, Medical Oncology Kirkner, Gregory J.; Dana-Farber Cancer Institute, Medical Oncology Meyer, Meghan E.; Dana-Farber Cancer Institute, Medical Oncology Tamimi, Rulla M. ; Weill Cornell Medical College, Population Health Sciences Schapira, Lidia; Stanford University, Department of Medicine, Division of Medical Oncology Peppercorn, Jeffrey; Massachusetts General Hospital, Department of Medicine, Division of Medical Oncology Come, Steven; Beth Israel Deaconess Medical Center, Medical Oncology Borges, Virginia; University of Colorado Denver, Medical Oncology Warner, Ellen; Sunnybrook Health Sciences Centre, Medical Oncology Gelber, Shari; Dana-Farber Cancer Institute, Medical Oncology Collins, Laura; Beth Israel Deaconess Medical Center, Pathology Winer, Eric P.; Dana-Farber Cancer Institute, Medical Oncology Partridge, Ann; Dana-Farber Cancer Institute, Medical Oncology
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Patient-centred medicine
Keywords:	ONCOLOGY, Breast tumours < ONCOLOGY, Quality of Life

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Cohort profile: Helping Ourselves, Helping Others - The Young Women's Breast Cancer Study**  
4  
5 **(YWS): A multi-site prospective cohort study to advance the understanding of breast cancer**  
6  
7 **diagnosed in women aged 40 and younger**  
8  
9

10  
11 Shoshana M. Rosenberg,<sup>1,2,3</sup> Yue Zheng,<sup>4</sup> Kathryn J. Ruddy,<sup>5</sup> Philip D. Poorvu,<sup>2,3</sup> Craig Snow,<sup>2,3</sup>  
12  
13 Gregory J. Kirkner,<sup>2,3</sup> Meghan E. Meyer,<sup>2,3</sup> Rulla M. Tamimi,<sup>1</sup> Lidia Schapira,<sup>6</sup> Jeffrey Peppercorn,<sup>7</sup>  
14  
15 Steven Come,<sup>8</sup> Virginia F. Borges,<sup>9</sup> Ellen Warner,<sup>10</sup> Shari Gelber,<sup>2,3</sup> Laura C. Collins,<sup>11</sup> Eric P.  
16  
17 Winer,<sup>2,3,12</sup> and Ann H. Partridge<sup>2,3</sup>  
18  
19

20  
21  
22  
23 <sup>1</sup>Population Health Sciences, Weill Cornell Medicine, New York, NY, USA (current affiliation); <sup>2</sup>Medical  
24  
25 Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; <sup>3</sup>Breast Oncology Program, Dana-Farber  
26  
27 Brigham Cancer Center, Boston, MA, USA; <sup>4</sup>Data Science, Dana-Farber Cancer Institute, Boston, MA,  
28  
29 USA; <sup>5</sup>Medical Oncology, Mayo Clinic, Rochester, MN, USA; <sup>6</sup>Department of Medicine, Division of  
30  
31 Medical Oncology, Stanford University, Stanford, CA, USA; <sup>7</sup>Department of Medicine, Division of Medical  
32  
33 Oncology, Massachusetts General Hospital, Boston MA, USA; <sup>8</sup>Medical Oncology, Beth Israel  
34  
35 Deaconess Medical Center, Boston, MA, USA; <sup>9</sup>Medical Oncology, University of Colorado Anschutz  
36  
37 Medical Campus, Aurora, CO, USA; <sup>10</sup>Department of Medicine, Division of Medical Oncology, Odette  
38  
39 Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; <sup>11</sup>Pathology, Beth Israel  
40  
41 Deaconess Medical Center, Boston, MA, USA; <sup>12</sup>Yale Cancer Center, New Haven, CT, USA (current  
42  
43 affiliation)  
44  
45

46  
47 **Corresponding author:**  
48

49  
50 Ann H. Partridge

51  
52 Dana-Farber Cancer Institute

53  
54 450 Brookline Avenue  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Boston, MA 02067

Tel: 617-632-3800

Email: [ann\\_partridge@dfci.harvard.edu](mailto:ann_partridge@dfci.harvard.edu)

**Word count:** 3841

**Figures:** 2

**Tables:** 3

**Supplemental tables:** 2

**Keywords:** young women; breast cancer; outcomes; cohort study

## **Abstract**

**Purpose:** Compared to older women diagnosed with breast cancer, younger women are more likely to die of breast cancer and more likely to suffer psychosocially in both the short and long-term. The Young Women's Breast Cancer Study (YWS) is a multisite prospective cohort study established to address gaps in our knowledge about this vulnerable and understudied population.

**Participants:** The YWS enrolled 1,302 women newly diagnosed with stage 0-IV breast cancer at age 40 years or younger at 13 academic and community sites in North America between 2006 and 2016. Longitudinal patient-reported outcome data are complemented by clinical data abstraction and biospecimen collection at multiple time-points.

**Findings to Date:** Key findings related to fertility include that nearly 40% of participants were interested in pregnancy following diagnosis; of those who reported interest, 10% pursued fertility preservation. Overall, approximately 10% of YWS participants became pregnant in the first 5 years after diagnosis; follow-up is ongoing for pregnancies after 5 years. Studies focused on psychosocial outcomes have characterized quality of life, post-traumatic stress, and fear of recurrence, with findings detailing the factors associated with the substantial psychosocial burden many young women face during and following active treatment. Multiple studies have leveraged YWS biospecimens, including whole exome sequencing of tumor analyses that revealed that select somatic alterations occur at different frequencies in young (age <35) versus older women with luminal A breast cancer, and a study that explored clonal hematopoiesis of indeterminate potential found it to be rare in young survivors.

**Future Plans:** With a median follow-up of approximately 10 years, the cohort is just maturing for many relevant long-term outcomes and provides outstanding opportunities to further study and build collaborations to address gaps in our knowledge, with the ultimate objective to improve care and outcomes for young women with breast cancer.

**Registration:** [clinicaltrials.gov, NCT01468246](https://clinicaltrials.gov/ct2/show/study/NCT01468246)

### **Strengths and Limitations**

- Established in 2006, the Young Women's Breast Cancer Study (YWS) is a multi-site, prospective cohort of women with young onset breast cancer.
- The YWS was designed to conduct regular medical record review and collect biospecimens and serial patient-reported outcomes.
- Eligibility criteria included: 1) female; 2) a new diagnosis of stage 0-IV breast cancer 3) age  $\leq 40$  years at diagnosis; and 4) ability to understand written and spoken English.
- Robust follow-up procedures optimize participant engagement and ensure accurate ascertainment of oncologic outcomes and vital status.
- Recruitment was hospital-based and may not be truly representative of the general population, potentially impacting generalizability.

## Introduction

Greater than 14,000 women aged 40 years and younger are diagnosed with breast cancer annually in the United States alone, with thousands more worldwide. Far less is known, however, about breast cancer in younger vs. older women. Further, recent population-based data have demonstrated that the incidence of breast cancer is growing in this population.[1 2] Breast cancer is the leading cause of cancer-related deaths in women under 40 years of age, and while improved over time, survival rates for young women with breast cancer remain lower compared to older women.[3 4] The reasons for the poorer outcomes experienced by young women as understood to date are complex and multifactorial. Compared to older women, young women are more likely to present with symptoms and at a more advanced stage, due in part to diagnostic delays and lack of screening in this population.[5 6] Breast cancers arising in young women tend to have more unfavorable pathologic features and aggressive subtypes, including greater proportions with luminal B, HER2-positive, or triple-negative disease.[7 8] Young women are at high risk of non-adherence to risk reducing adjuvant hormonal therapy.[9-11] Compounding their disparate disease outcomes, young breast cancer survivors may be at greater risk of long-term or late morbidity given the aggressive therapy that they usually receive and anticipated long life trajectory in survivorship, although there are limited data in this area.

Of particular significance are the variety of young age-related medical and psychosocial issues that this population faces as a result of their diagnosis and treatment, which contribute to a greater risk of psychosocial distress compared to older patients.[12] These issues include hereditary predisposition and risks of future cancer, sexual dysfunction, infertility, premature menopause, body image concerns, role functioning including parenting, career and schooling disruption and the development of short- and long-term comorbidities. Collectively, these problems may influence treatment decisions, as well as disease and psychosocial outcomes.



## ***Purpose of the Young Women's Breast Cancer Study***

Young women are underrepresented in large prospective cohorts as well as in randomized trials evaluating novel therapies and prognostic tools to guide breast cancer treatment decisions.[13-15] Hesitancy to extrapolate data from studies of primarily older populations may result in young women being excluded or delayed in benefits from treatment improvements, or put at risk for overtreatment based solely on young age. Even in large prospective cohort studies and clinical trials inclusive of premenopausal women, as well as in population-based registries, there are rarely enough young women and/or adequate granularity of data to draw meaningful conclusions for this subpopulation. For example, the Nurses' Health Studies have previously reported 374 incident cases age <40 years (vs. 2,533 cases in women age ≥40),[16] the Black Women's Health Study had 529 cases of breast cancer diagnosed at age <45 years documented through 2013 (vs. 1,534 cases in women aged 45 and older),[17] and the Suppression of Ovarian Function Trial had 933 participants age <40 years at diagnosis,[18] with limited details in follow-up for most. The Young Women's Breast Cancer Study (YWS) was designed to address gaps in knowledge regarding breast cancer in younger women, including unanswered questions pertaining to diagnosis and presentation, underlying disease biology, optimal treatment, survivorship, psychosocial issues, and living with metastatic disease. The YWS is the first and one of the largest cohorts of women with young onset breast cancer designed to conduct regular medical record review and collect biospecimens and patient-reported outcomes (PROs) (**Figure 1**). The original study objectives were to 1) enroll a cohort of women age ≤40 years newly diagnosed with breast cancer; 2) characterize the cohort at diagnosis and in follow-up regarding disease and psychosocial outcomes; and 3) archive tumor and blood specimens for future studies.

## **Cohort Description**

### ***Overview***

From 2006-2016, the YWS enrolled 1,302 women from 13 North American academic and community sites (**Supplemental Table 1**). There was high accrual of those approached for enrollment

(1302/2186, 60% participate rate). Four patients were determined to be ineligible, and one withdrew consent following enrollment leaving 1,297 women who are followed. Reasons for non-participation are detailed in **Figure 2**. The YWS is approved by the Institutional Review Board at Dana-Farber Harvard Cancer Center (DF/HCC) and other participating sites.

### ***Enrollment procedures***

At Massachusetts sites, potentially eligible participants were systematically identified by pathology review or by pathology or clinic list review by a research nurse on a monthly or bi-monthly basis. The Dana-Farber Cancer Institute (DFCI) Survey and Data Management Core then reviewed the medical record to confirm eligibility. At sites outside of Massachusetts, study staff assisted with recruitment via systematic review of patient lists. Eligibility was confirmed prior to inviting. Inclusion criteria included: 1) female; 2) a new diagnosis of stage 0-IV breast cancer 3) age  $\leq 40$  years at diagnosis; and 4) ability to understand written and spoken English to the extent necessary to complete the questionnaires. Participants enrolled a median of 4 (range: 0-29) months following diagnosis. Following receipt of written informed consent, participants were mailed a welcome letter, medical record release form, tumor specimen request form, and the baseline survey. Current median follow-up of the cohort is 10 years (range: 0.4-16 years).

### ***Participant characteristics***

**Table 1** includes a summary of YWS participant age at diagnosis, race, and ethnicity. Baseline survey questions asked participants about their race and ethnicity. For baseline survey non-responders or instances where this information was not reported, race/ethnicity as determined from medical record at screening/enrollment was used. Approximately 14% of YWS participants are from a non-White and/or Hispanic racial/ethnic background. Median age at diagnosis was 36 (range: 17-40) years. Key cancer information including stage, grade, subtype, and BRCA mutation status is detailed in **Table 2**. Recognizing that there have been changes in how we measure social determinants of health since the baseline survey was developed and to make these data more complete, we are sending YWS

1  
2  
3 participants a supplemental survey including updated questions regarding race, ethnicity, gender, and  
4  
5 sexual identity.  
6

### 7 ***Patient and Public Involvement***

8  
9  
10 Since the study's inception, we have invited patient volunteers and patient advocates to review  
11  
12 survey content as well as assist with strategies to communicate results to YWS participants and other  
13  
14 young patients. We routinely share lay summary results from YWS analyses directly through the DFCI  
15  
16 Program for Young Adults with Breast Cancer newsletter as well as intermittent webinars and patient  
17  
18 forums. Newsletters and webinars are also archived on the program's public website  
19  
20 (<https://youngandstrong.dana-farber.org>).  
21  
22

### 23 ***YWS Data Collection and Follow-up***

24  
25  
26 *Surveys:* Participants completed surveys at study baseline (median of 5 months post-diagnosis), 6  
27  
28 months after enrollment, and 1-year post-diagnosis. Participants were then surveyed every 6 months  
29  
30 through 3 years, and annually thereafter. Participants enrolled at the Toronto site (N=62) are sent  
31  
32 abbreviated ("short-form") surveys that ask for socio-demographics, how their breast cancer presented,  
33  
34 fertility and gynecologic information, and cancer endpoints. At the 10-year timepoint, Toronto  
35  
36 participants are sent a full survey to complete. A smaller subset of participants (N=29) who enrolled at  
37  
38 other sites chose to complete the short-form follow-up annual surveys that only ask about fertility,  
39  
40 gynecologic and cancer outcomes. For the initial 7 years of the YWS, all surveys were mailed to main  
41  
42 study participants; participants completing short-form surveys were given the option of completing  
43  
44 surveys on paper or online via Survey Monkey. Beginning at the 8-year survey time point, participants  
45  
46 were offered the option to complete an electronic survey through REDCap. In March 2020, due to  
47  
48 COVID restrictions limiting the ability to mail materials, participants with a valid email address (98%)  
49  
50 were sent surveys through REDCap. Collectively, these surveys have yielded an unparalleled resource  
51  
52 of longitudinal PRO data related to menopausal status, fertility, anxiety, depression, quality of life  
53  
54 (QOL), fear of recurrence, treatment side-effects, employment, genetics, and treatment decision-  
55  
56  
57  
58  
59  
60

1  
2  
3 making (see **Table 3** for domains/timeline for the first 15 years of follow-up). We also periodically invite  
4 participant subsets to complete supplemental surveys to investigate salient issues in greater detail.[19-  
5  
6  
7 24]

8  
9 *Follow-up to optimize survey response rates:* A research coordinator systematically contacts  
10 participants who do not complete their surveys with a phone call at 3 weeks after the initial survey is  
11 sent out; the survey is re-sent at 6 weeks if the participant has still not completed the survey at that  
12 timepoint. Additional calls and/or survey resends are then conducted monthly up to 6 months following  
13 the initial send out, as needed. Response rates (surveys received/surveys sent) for the majority of  
14 survey time points range from 86%-91%. Response rates for 7 and 10-year surveys are modestly lower  
15 (71% for 7-year and 65% for 10-year) due to our attempt to re-engage non-responding participants at  
16 those timepoints.  
17  
18  
19  
20  
21  
22  
23  
24  
25

26  
27 *Medical Records:* Medical records through the first 18 months following diagnosis are available for  
28 100% of participants. Records are also reviewed at additional timepoints (including at 10 years) to 1)  
29 confirm and collect specifics on cancer outcomes (recurrences, new primary breast cancers, other  
30 cancers) that are self-reported on surveys; and 2) to update comorbidities including recurrences and  
31 new cancers and vital status among participants who do not regularly complete surveys. We have  
32 abstracted initial treatment information, including specific chemotherapy regimens started and received,  
33 surgery, radiation, genetic testing (panel type and results), and co-morbidities using the Charlson  
34 framework[25 26] from the medical record to validate/supplement what patients report on surveys, and  
35 to fill in missing data.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 *Ascertainment of Cancer Outcomes and Vital Status:* Recurrences, new primary breast cancers, and  
47 new (non-breast) cancers are assessed on each survey. In addition to site(s) of recurrence or new  
48 cancer, participants are asked to report the date of the recurrence. Any self-report of a recurrence or  
49 new cancer, including site and date (either radiologic or pathologic confirmation) is confirmed by  
50 medical record review. Because this process relies on survey responses to ascertain outcomes, for  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 those participants who are no longer responding to surveys we request and review updated medical  
4 records for these patients every 4 years. For participants treated at DFCI, Brigham and Women's  
5 Hospital, Massachusetts General Hospital or an affiliate network site, the National Death Index is  
6 queried periodically to obtain vital status information. Following the 2018-2019 update, we were able to  
7 ascertain oncologic outcomes and vital status for 321 patients who were survey non-responders. As of  
8 September 2023, among the entire cohort, we have documented 181 participants with distant  
9 metastatic recurrences, 96 participants with locoregional recurrences, 22 participants with new primary  
10 breast cancers, and 49 participants with new non-breast primary cancers, and 186 deaths.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20 *Tissue Specimen Collection/Storage:* Pathology reports, hematoxylin and eosin (H&E) stained slides,  
21 and a representative paraffin block of tumor were requested from the institution where the patient had  
22 her surgery; the patient's signed release for the specimens and reports were sent to the pathology  
23 department. A YWS study pathologist reviewed each pathology report and an H&E stained section of  
24 the tumor block to annotate tumor details.[8 27] Slides from the core needle biopsy were requested as  
25 well as from the surgery in neoadjuvant therapy cases. Hormone and HER-2/neu (HER2) receptor  
26 expression, and lymph node status, were extracted from the pathology reports. Of 1297 participants  
27 followed, 1278 (99%) consented to providing a tumor specimen for review. Primary tumor pathology  
28 has been centrally reviewed on 97% of patients (1242/1278), with blocks (N=1120) and cores for the  
29 tissue microarray (N=21) from tumor specimens collected on 1141 patients (88%). Currently, there are  
30 1370 specimens from 1242 patients available in the tissue microarray blocks (patients who received  
31 neoadjuvant therapy may have more than one block).

32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46 *Blood Collection/Storage:* Blood is collected at three timepoints (two 10mL tubes of whole blood at  
47 each timepoint), each with a several month "window" to maximize our ability to collect blood while  
48 minimizing burden: baseline (enrollment up to 9 months post-diagnosis); 1-year (9 months-2 years  
49 post-diagnosis); and 4-year (3.5 – 5 years post diagnosis). Overall, 94% (1224/1297) of participants  
50 consented to blood collection. Of these, there is at least one sample available from 92% of participants,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 with 73% of participants providing samples at two or more time points (**Supplemental Table 2**).

4  
5 Women were asked to go to their treating institution or a local laboratory with the materials provided in  
6  
7 the blood specimen kit, unless drawn at DFCI where kits are provided on site by staff. Specimens were  
8  
9 processed at the DFCI Breast Cancer CORE Blood Repository, where whole blood (4 aliquots/2ml  
10  
11 each) and plasma (2 aliquots/2mL each) were isolated and banked for future studies.  
12

### 13 14 **Findings to Date**

15  
16 Since its inception, YWS investigations have characterized more fully the experience of breast  
17  
18 cancer in young women, creating a platform from which to study molecular and biologic issues, as well  
19  
20 as the health and psychosocial repercussions of a breast cancer diagnosis and treatment at a young  
21  
22 age. As the YWS has matured, we have expanded our investigations to include collaborations with  
23  
24 basic and translational scientists enabling us to address new questions, advancing knowledge of the  
25  
26 biology of the disease as well as to improve clinical care and outcomes. In addition, research findings  
27  
28 from the YWS have informed international guidelines and clinical practice.[28 29]  
29  
30

### 31 32 ***Fertility Issues and Pregnancy***

33  
34 In 2014, we published findings from the baseline survey regarding fertility concerns and fertility  
35  
36 preservation strategies used.[30] Since then, additional publications from the YWS have described  
37  
38 breast cancer diagnosed during pregnancy,[31] pregnancy after breast cancer,[32] treatment-related  
39  
40 amenorrhea,[33] fertility concerns and endocrine therapy decision-making,[34] and fertility concerns in  
41  
42 germline genetic carriers.[35] Key findings included the observation that nearly 40% of participants  
43  
44 were interested in pregnancy after breast cancer; of those interested, 10% pursued fertility preservation  
45  
46 strategies.[30] Another study documented that approximately 20% of women become amenorrheic in  
47  
48 survivorship after standard chemotherapy, with variability by chemotherapy type and age.[33] A third  
49  
50 study evaluated post-diagnosis pregnancies, observing that 10% became pregnant in the first 5 years  
51  
52 after breast cancer.[32] Fertility outcomes remain a primary outcome of interest in continued follow-up  
53  
54 of the cohort and the rich and detailed fertility and gynecologic data collected at each time point will  
55  
56  
57  
58  
59  
60

1  
2  
3 allow for novel and detailed investigations regarding impact of pregnancy on cancer endpoints, and  
4 menopausal and related comorbidity outcomes. Findings from this work have been referenced in  
5 international guidelines[28 29] and informed an international trial that evaluated the safety of pregnancy  
6 after breast cancer.[36] We are also participating in an international, multi-site, retrospective cohort  
7 study (PI: Dr. Matteo Lambertini, University of Genoa, IT) inclusive of >1400 patients with BRCA+  
8 breast cancer from 30 sites across North America, Europe, Latin America, and Israel, contributing  
9 clinical, genetic, and PRO data on 125 YWS participants with BRCA mutations. To date, there have  
10 been two major publications reporting analyses of pregnancy outcomes as well as clinical outcomes  
11 from this collaboration.[37 38]  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

### ***Systemic Treatment and Disease Recurrence and Response***

23  
24  
25 In 2017, we conducted a study examining the prognostic value of genomic expression prediction  
26 assays in the YWS. Prior research that led to the routine incorporation of such tools into clinical care  
27 had included relatively few women <40 years old, resulting in hesitation among providers to use them  
28 for young women. We demonstrated that Recurrence Score (RS) was prognostic and appeared to be  
29 predictive of chemotherapy benefit or lack thereof in patients with node-negative disease.[39] These  
30 data have informed recent guidelines and clinical practice supporting the use of RS in young patients to  
31 influence chemotherapy decisions.[28] We subsequently demonstrated the association of RS with  
32 pathologic complete response (pCR) after neoadjuvant chemotherapy for hormone receptor-positive  
33 disease[40]; results from this study are providing preliminary data for planned correlative work in a pre-  
34 operative clinical trial in the Alliance for Clinical Trials in Oncology.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

### ***Psychosocial Implications of Breast Cancer in Young Women***

47  
48  
49 A large focus of the YWS has been to study the early psychological and social repercussions of  
50 breast cancer in young women to identify areas for tailored support and management strategies. We  
51 have characterized sexual functioning and body image issues, the impact of a diagnosis on  
52 employment, post-traumatic stress, fear of recurrence, anxiety and depression in women with de novo  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 stage IV disease, as well as the impact of the diagnosis on the partners of YWS participants.[41-48]  
4  
5 Recent studies have found that more extensive surgery and radiation are associated with poorer  
6  
7 QOL[21 49] as well as increased arm morbidity.[50] Collectively, our findings indicate that young  
8  
9 women experience a substantial psychosocial burden during and following the completion of active  
10  
11 treatment, and this burden is associated with certain patient, disease and treatment variables which can  
12  
13 be targeted for intervention.  
14  
15

### 16 ***Biological Differences in Breast Cancer by Age***

17  
18 Collaborative efforts have yielded important findings to date including a comparison of whole  
19  
20 exome sequencing profiles of the youngest 100 participants ( $\leq 35$  years at diagnosis) to older women  
21  
22 from The Cancer Genome Atlas (TCGA).[51 52] This analysis revealed that somatic alterations in three  
23  
24 genes (*PIK3CA*, *GATA3*, and *ARID1A*) occur at different frequencies in young versus older women with  
25  
26 luminal A breast cancer.[52] Additional investigation of these genes could delineate biological  
27  
28 susceptibilities for young patients. Several additional studies have used or pooled tissue and/or blood  
29  
30 specimens including a genome wide association study characterizing single nucleotide polymorphisms  
31  
32 in young patients,[53] a study of RasGAP genes in luminal B tumors,[54] and a study of somatic  
33  
34 mutations in patients with metastatic triple negative breast cancer,[55] and the development of a test to  
35  
36 identify minimal residual disease in early-stage breast cancer.[51] Most recently, we used novel DNA  
37  
38 sequencing methods to evaluate the prevalence and mutation spectrum of clonal hematopoiesis in  
39  
40 young women and its association with patient and treatment characteristics and outcomes.[56]  
41  
42 Reassuringly, clonal hematopoiesis of indeterminate potential (CHIP) was rare, with a prevalence of  
43  
44  $<3\%$  among the 878 women in the analytic cohort.[56] The YWS has also provided clinical data  
45  
46 detailing cancer outcomes of nulliparous vs. recently parous women, for an analysis supporting the  
47  
48 novel pre-clinical finding that weaning-induced liver involution establishes a pro-metastatic  
49  
50 microenvironment, a potential explanation for more poor cancer outcomes of recently parous  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 women.[57] Several analyses to understand the biologic underpinnings of early onset breast cancer are  
4  
5 underway.  
6  
7

### 8 9 **Collaboration**

10  
11 The YWS is uniquely positioned for investigations of age-related tumor and host biology as well  
12  
13 as studies evaluating the impact of hereditary predisposition, post-diagnosis pregnancy, premature  
14  
15 menopause, psychosocial, lifestyle and care delivery on cancer endpoints and comorbidities. The YWS  
16  
17 research team includes medical, surgical, and radiation oncologists, epidemiologists, pathologists, and  
18  
19 biostatisticians, and our collaborations have grown to include experts in cancer genomics, biology,  
20  
21 tumor microenvironment, and behavioral health. While data are not publicly available, investigators  
22  
23 interested in accessing YWS-generated data and/or biospecimens should contact the Principal  
24  
25 Investigator (A. Partridge) and submit a request to the DF/HCC breast users committee  
26  
27 ([https://www.dfhcc.harvard.edu/research/research-programs/clinical-based-programs/breast-](https://www.dfhcc.harvard.edu/research/research-programs/clinical-based-programs/breast-cancer/program-resources/dfhcc-breast-users-committee/)  
28  
29 [cancer/program-resources/dfhcc-breast-users-committee/](https://www.dfhcc.harvard.edu/research/research-programs/clinical-based-programs/breast-cancer/program-resources/dfhcc-breast-users-committee/)).  
30  
31  
32

### 33 **Future Directions**

34  
35 The YWS has proven to be a rich scientific resource that has resulted in impactful research that  
36  
37 has advanced our understanding of breast cancer in young women, generated new lines of  
38  
39 investigation, and informed clinical guidelines. Breast cancer is the leading cause of cancer-related  
40  
41 deaths in young women, and while improved over time, survival rates for young women with breast  
42  
43 cancer remain lower compared to older women.[3 4] Thus, identifying risk factors for these poorer  
44  
45 outcomes in younger women is critical. With the cohort maturing, we expect the number of recurrent  
46  
47 disease events expected to increase by ~50% over the next 5 years and beyond, allowing for further  
48  
49 evaluation of predictors of oncologic outcomes, including breast cancer free survival and overall  
50  
51 survival. With relatively large numbers of young patients treated with contemporary regimens and well-  
52  
53 annotated treatment details, we will be well-positioned to evaluate the impact of post-diagnosis  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 pregnancies on recurrence, new primary cancer, or death, assessment of risk factors for second  
4 cancers by breast cancer phenotype and germline pathogenic variant status, as well as risk factors for  
5 late recurrences among women diagnosed at a young age. Studies of the role of ctDNA on predicting  
6 late recurrence and exploring tumor and host characteristics that may be conducive to  
7 recurrence/disease resistance to therapy in young women (e.g., tumor immune microenvironment  
8 differences by recent parity status at diagnosis) have great potential.  
9  
10  
11  
12  
13  
14  
15

16 As a survivorship cohort, evaluating long-term, late effects of breast cancer treatment and  
17 survivorship is a central objective of the YWS. A critical charge of cancer survivorship research is  
18 identifying potentially modifiable factors that predict these risks. Young breast cancer survivors may be  
19 at high risk of long-term or late morbidity given the aggressive therapy they usually receive and  
20 anticipated long life trajectory after the cancer. Additionally, they may have hereditary, behavioral, and  
21 comorbidity predispositions to disease. The concerns unique to or accentuated by their stage of life at  
22 diagnosis also appear to contribute to the increased risk of psychological distress seen in this age  
23 group both at diagnosis and in long-term follow-up.[12] With a median follow-up of 10 years, we are  
24 now well-poised to study late and long-term morbidity, including premature menopause (age <45  
25 years), which in non-cancer populations is associated with substantial multimorbidity including  
26 increased risk of depression, hyperlipidemia, heart disease, asthma, chronic obstructive pulmonary  
27 disease, arthritis and osteoporosis.[58] On each survey, YWS participants are asked about their  
28 menstrual status, including date of last menstrual period, reasons for periods stopping, as well as  
29 questions about gynecologic procedures providing granular data to inform analyses. Given the current  
30 age of the cohort, the next several years are a critical time to conduct in-depth assessment of the  
31 menopausal transition among women who remained premenopausal following treatment, including  
32 timing, risk factors for premature menopause, and the impact of early menopause on QOL and  
33 comorbidities in this population. This data resource will also facilitate investigations ranging from health  
34 care utilization assessments, changes in lifestyle factors over time, and trajectories of QOL, to  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 evaluations of the association of specific co-morbidities (e.g., heart disease, diabetes) with premature  
4 menopause, weight gain, body composition, metabolic biomarkers, inflammatory mediators, hormone  
5 levels, and biomarkers of accelerated aging.  
6  
7  
8  
9

### 10 11 12 **Strengths and Limitations**

13  
14  
15 With a repository of biospecimens, clinical data, and serial PRO collection, the YWS is a robust  
16 platform from which to study molecular and biologic issues, as well as the health and psychosocial  
17 repercussions of a breast cancer diagnosis and treatment in young women. One of the core strengths  
18 of the YWS is high participant engagement, which has facilitated our ability to follow participants for  
19 both medical and psychosocial outcomes in extended follow-up. Additionally, we have leveraged the  
20 collection of blood specimens at three time points – baseline, 1 year, and 4 years after diagnosis – for  
21 novel investigations that are complemented with clinical data that have been systematically abstracted  
22 from the medical record. However, as the YWS is an observational cohort study, establishing causality  
23 vs. association can be challenging and there is a risk of unmeasured or unaccounted for confounders in  
24 analyses. As the main objective of the YWS was to establish a survivorship cohort that followed young  
25 women diagnosed with breast cancer, women older than 40 and women without a history of cancer  
26 were not enrolled; thus, our study is not designed to enable cross-age comparisons or comparisons  
27 with non-cancer, age-matched “controls.” Additionally, while the YWS is a multi-site study that included  
28 both academic and community sites, women enrolled in the YWS are predominantly white, non-  
29 Hispanic, and highly educated, which may impact generalizability of findings to young breast cancer  
30 survivors from more diverse racial, ethnic, and socio-economic backgrounds. Acknowledging this  
31 limitation, more recent studies conducted by our team, including intervention trials informed by YWS  
32 findings, have focused efforts to improve outreach to patients from historically under-represented racial  
33 and ethnic groups.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Data availability statement:** Requests to access YWS data/biospecimens should be made to the  
4 Principal Investigator, Dr. Ann Partridge ([ann\\_partridge@dfci.harvard.edu](mailto:ann_partridge@dfci.harvard.edu)).

5  
6  
7 **Acknowledgements:** We thank all participants for their past and continued contributions to the YWS  
8 study. We also thank Ms. Kate Bifolck for editorial and submission assistance; she is a full-time  
9 employee of Dana-Farber Cancer Institute.

10  
11  
12  
13  
14 **Funding:** Susan G. Komen (SAC100008, Partridge) and Breast Cancer Research Foundation (BCRF-  
15 21-124, Partridge)

16  
17  
18 **Ethics statements:** The YWS is approved by the Institutional Review Board at Dana-Farber Harvard  
19 Cancer Center (IRB# 06-169) and other participating sites. Participants provided written informed  
20 consent at the time of enrollment.

21  
22  
23  
24  
25  
26 **Competing Interests:** SMR reports grant funding from Conquer Cancer/Pfizer. VB reports research  
27 funding (paid to institution) from SeaGen, AstraZeneca, Gilead, and Olema; consultation for SeaGen,  
28 AstraZeneca, Lilly, Gilead, and Olema; and stock/founder of PEARL Scientific. AHP reports royalties  
29 from Wolters Kluwer (paid to self) for authorship of UpToDate. All remaining authors have no  
30 disclosures to report.

31  
32  
33  
34  
35  
36  
37 **Author contributions:** AHP, EPW, RMT, and SG conceptualized and developed the cohort and  
38 methodology. LCC provided oversight for pathology review. MEM, CS, and GJK have supported data  
39 and biospecimen collection and management. SG and YZ have provided statistical support. KJR, LS,  
40 JP, SC, VFB, and EW have served as site investigators. AHP, KJR, and PDP provided oversight for  
41 medical record/clinical data review. AHP and SMR provide general oversight and management of the  
42 study. AHP provided funding for the study. AHP is the guarantor of the study. All authors read and  
43 approved the final manuscript.

## REFERENCES

1. Ellington TD, Miller JW, Henley SJ, et al. Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age Among Women Aged  $\geq 20$  Years - United States, 1999-2018. *MMWR Morb Mortal Wkly Rep* 2022;71(2):43-47. doi: 10.15585/mmwr.mm7102a2
2. Miller KD, Fidler-Benaoudia M, Keegan TH, et al. Cancer statistics for adolescents and young adults, 2020. *CA Cancer J Clin* 2020;70(6):443-59. doi: 10.3322/caac.21637
3. Guo F, Kuo Y-f, Shih YCT, et al. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. *Cancer* 2018;124(17):3500-09. doi: <https://doi.org/10.1002/cncr.31638>
4. Kim HJ, Kim S, Freedman RA, et al. The impact of young age at diagnosis (age  $< 40$  years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. *The Breast* 2022;61:77-83. doi: <https://doi.org/10.1016/j.breast.2021.12.006>
5. Partridge AH, Hughes ME, Ottesen RA, et al. The effect of age on delay in diagnosis and stage of breast cancer. *Oncologist* 2012;17(6):775-82. doi: 10.1634/theoncologist.2011-0469
6. Zabicki K, Colbert JA, Dominguez FJ, et al. Breast cancer diagnosis in women  $\leq 40$  versus 50 to 60 years: increasing size and stage disparity compared with older women over time. *Ann Surg Oncol* 2006;13(8):1072-7. doi: 10.1245/ASO.2006.03.055
7. Azim HA, Jr., Partridge AH. Biology of breast cancer in young women. *Breast Cancer Res* 2014;16(4):427. doi: 10.1186/s13058-014-0427-5
8. Guzman-Arocho YD, Rosenberg SM, Garber JE, et al. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. *Br J Cancer* 2022;126(2):302-09. doi: 10.1038/s41416-021-01597-2
9. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. *Breast Cancer Res Treat* 2011;126(2):529-37. doi: 10.1007/s10549-010-1132-4
10. Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. *J Clin Oncol* 2003;21(4):602-6. doi: 10.1200/JCO.2003.07.071
11. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. *J Clin Oncol* 2010;28(27):4120-8. doi: 10.1200/JCO.2009.25.9655
12. Howard-Anderson J, Ganz PA, Bower JE, et al. Quality of Life, Fertility Concerns, and Behavioral Health Outcomes in Younger Breast Cancer Survivors: A Systematic Review. *J Natl Cancer Inst* 2012 doi: djr541

13. Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med* 2016;375(8):717-29. doi: 10.1056/NEJMoa1602253
14. Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. *N Engl J Med* 2021;385(25):2336-47. doi: 10.1056/NEJMoa2108873
15. Sparano JA, Gray RJ, Makower DF, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med* 2015;373(21):2005-14. doi: 10.1056/NEJMoa1510764
16. Warner ET, Colditz GA, Palmer JR, et al. Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40? *Breast Cancer Res Treat* 2013;142(1):165-75. doi: 10.1007/s10549-013-2721-9
17. Bertrand KA, Bethea TN, Adams-Campbell LL, et al. Differential Patterns of Risk Factors for Early-Onset Breast Cancer by ER Status in African American Women. *Cancer Epidemiol Biomarkers Prev* 2017;26(2):270-77. doi: 10.1158/1055-9965.EPI-16-0692
18. Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N Engl J Med* 2018;379(2):122-37. doi: 10.1056/NEJMoa1803164
19. Borstelmann NA, Gray TF, Gelber S, et al. Psychosocial issues and quality of life of parenting partners of young women with breast cancer. *Support Care Cancer* 2022 doi: 10.1007/s00520-022-06852-7
20. Borstelmann NA, Rosenberg S, Gelber S, et al. Partners of young breast cancer survivors: a cross-sectional evaluation of psychosocial concerns, coping, and mental health. *J Psychosoc Oncol* 2020;38(6):670-86. doi: 10.1080/07347332.2020.1823546
21. Dominici L, Hu J, Zheng Y, et al. Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. *JAMA Surg* 2021;156(10):e213758. doi: 10.1001/jamasurg.2021.3758
22. Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. *Ann Intern Med* 2013;159(6):373-81. doi: 10.7326/0003-4819-159-6-201309170-00003
23. Walker HE, Rosenberg SM, Stanton AL, et al. Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer. *J Adolesc Young Adult Oncol* 2016;5(1):16-23. doi: 10.1089/jayao.2015.0051
24. Sella T, Fell GG, Miller PG, et al. Patient perspectives on testing for clonal hematopoiesis of indeterminate potential. *Blood Adv* 2022;6(24):6151-61. doi: 10.1182/bloodadvances.2022008376

- 1  
2  
3 25. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in  
4 longitudinal studies: development and validation. *J Chronic Dis* 1987;40(5):373-83. doi:  
5 10.1016/0021-9681(87)90171-8  
6  
7  
8 26. Sangha O, Stucki G, Liang MH, et al. The Self-Administered Comorbidity Questionnaire: a new  
9 method to assess comorbidity for clinical and health services research. *Arthritis Rheum*  
10 2003;49(2):156-63. doi: 10.1002/art.10993  
11  
12 27. Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age  
13 in a large cohort of young women with breast cancer. *Breast Cancer Res Treat*  
14 2012;131(3):1061-6. doi: 10.1007/s10549-011-1872-9  
15  
16  
17 28. Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO 4th International Consensus  
18 Guidelines for Breast Cancer in Young Women (BCY4). *Ann Oncol* 2020;31(6):674-96. doi:  
19 10.1016/j.annonc.2020.03.284  
20  
21  
22 29. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO  
23 Clinical Practice Guideline Update. *J Clin Oncol* 2018;36(19):1994-2001. doi:  
24 10.1200/JCO.2018.78.1914  
25  
26  
27 30. Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation  
28 strategies in young women with breast cancer. *J Clin Oncol* 2014;32(11):1151-6. doi:  
29 10.1200/JCO.2013.52.8877  
30  
31 31. Lee GE, Rosenberg SM, Mayer EL, et al. Contemporary management of breast cancer during  
32 pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer.  
33 *Breast J* 2019;25(6):1104-10. doi: 10.1111/tbj.13431  
34  
35  
36 32. Poorvu PD, Gelber SI, Zheng Y, et al. Pregnancy after breast cancer: Results from a prospective  
37 cohort of young women with breast cancer. *Cancer* 2021;127(7):1021-28. doi:  
38 10.1002/cncr.33342  
39  
40  
41 33. Poorvu PD, Hu J, Zheng Y, et al. Treatment-related amenorrhea in a modern, prospective cohort  
42 study of young women with breast cancer. *NPJ Breast Cancer* 2021;7(1):99. doi:  
43 10.1038/s41523-021-00307-8  
44  
45  
46 34. Sella T, Poorvu PD, Ruddy KJ, et al. Impact of fertility concerns on endocrine therapy decisions in  
47 young breast cancer survivors. *Cancer* 2021;127(16):2888-94. doi: 10.1002/cncr.33596  
48  
49  
50 35. Lewinsohn R, Zheng Y, Rosenberg SM, et al. Fertility Preferences and Practices Among Young  
51 Women With Breast Cancer: Germline Genetic Carriers Versus Noncarriers. *Clin Breast Cancer*  
52 2023;23(3):317-23. doi: 10.1016/j.clbc.2022.12.012  
53  
54  
55 36. Partridge AH, Niman SM, Ruggeri M, et al. Interrupting Endocrine Therapy to Attempt Pregnancy  
56 after Breast Cancer. *N Engl J Med* 2023;388(18):1645-56. doi: 10.1056/NEJMoa2212856  
57  
58  
59  
60

- 1  
2  
3 37. Lambertini M, Ameye L, Hamy AS, et al. Pregnancy After Breast Cancer in Patients With Germline  
4 BRCA Mutations. *J Clin Oncol* 2020;38(26):3012-23. doi: 10.1200/JCO.19.02399  
5  
6  
7 38. Lambertini M, Ceppi M, Hamy AS, et al. Clinical behavior and outcomes of breast cancer in young  
8 women with germline BRCA pathogenic variants. *NPJ Breast Cancer* 2021;7(1):16. doi:  
9 10.1038/s41523-021-00224-w  
10  
11 39. Poorvu PD, Gelber SI, Rosenberg SM, et al. Prognostic Impact of the 21-Gene Recurrence Score  
12 Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-  
13 Negative Breast Cancer. *J Clin Oncol* 2020;38(7):725-33. doi: 10.1200/JCO.19.01959  
14  
15  
16 40. Sella T, Gelber SI, Poorvu PD, et al. Response to neoadjuvant chemotherapy and the 21-gene  
17 Breast Recurrence Score test in young women with estrogen receptor-positive early breast  
18 cancer. *Breast Cancer Res Treat* 2021;186(1):157-65. doi: 10.1007/s10549-020-05989-5  
19  
20  
21 41. Borstelmann NA, Rosenberg SM, Ruddy KJ, et al. Partner support and anxiety in young women  
22 with breast cancer. *Psychooncology* 2015;24(12):1679-85. doi: 10.1002/pon.3780  
23  
24 42. Rosenberg SM, Vaz-Luis I, Gong J, et al. Employment trends in young women following a breast  
25 cancer diagnosis. *Breast Cancer Res Treat* 2019;177(1):207-14. doi: 10.1007/s10549-019-  
26 05293-x  
27  
28  
29 43. Vazquez D, Rosenberg S, Gelber S, et al. Posttraumatic stress in breast cancer survivors  
30 diagnosed at a young age. *Psychooncology* 2020;29(8):1312-20. doi: 10.1002/pon.5438  
31  
32  
33 44. Park EM, Gelber S, Rosenberg SM, et al. Anxiety and Depression in Young Women With  
34 Metastatic Breast Cancer: A Cross-Sectional Study. *Psychosomatics* 2018;59(3):251-58. doi:  
35 10.1016/j.psych.2018.01.007  
36  
37 45. von Hippel C, Rosenberg SM, Austin SB, et al. Identifying distinct trajectories of change in young  
38 breast cancer survivors' sexual functioning. *Psychooncology* 2019;28(5):1033-40. doi:  
39 10.1002/pon.5047  
40  
41  
42 46. Rosenberg SM, Tamimi RM, Gelber S, et al. Treatment-related amenorrhea and sexual functioning  
43 in young breast cancer survivors. *Cancer* 2014;120(15):2264-71. doi: 10.1002/cncr.28738  
44  
45  
46 47. Rosenberg SM, Tamimi RM, Gelber S, et al. Body image in recently diagnosed young women with  
47 early breast cancer. *Psychooncology* 2013;22(8):1849-55. doi: 10.1002/pon.3221  
48  
49  
50 48. Schapira L, Zheng Y, Gelber SI, et al. Trajectories of fear of cancer recurrence in young breast  
51 cancer survivors. *Cancer* 2022;128(2):335-43. doi: 10.1002/cncr.33921  
52  
53 49. Rosenberg SM, Dominici LS, Gelber S, et al. Association of Breast Cancer Surgery With Quality of  
54 Life and Psychosocial Well-being in Young Breast Cancer Survivors. *JAMA Surg*  
55 2020;155(11):1035-42. doi: 10.1001/jamasurg.2020.3325  
56  
57  
58  
59



- 1  
2  
3 50. Kuijter A, Dominici LS, Rosenberg SM, et al. Arm Morbidity After Local Therapy for Young Breast  
4 Cancer Patients. *Ann Surg Oncol* 2021;28(11):6071-82. doi: 10.1245/s10434-021-09947-3  
5  
6  
7 51. Parsons HA, Rhoades J, Reed SC, et al. Sensitive Detection of Minimal Residual Disease in  
8 Patients Treated for Early-Stage Breast Cancer. *Clin Cancer Res* 2020;26(11):2556-64. doi:  
9 10.1158/1078-0432.CCR-19-3005  
10  
11 52. Waks AG, Kim D, Jain E, et al. Somatic and germline genomic alterations in very young women  
12 with breast cancer. *Clin Cancer Res* 2022 doi: 10.1158/1078-0432.CCR-21-2572  
13  
14  
15 53. Rath M, Li Q, Li H, et al. Evaluation of significant genome-wide association studies risk - SNPs in  
16 young breast cancer patients. *PLoS One* 2019;14(5):e0216997. doi:  
17 10.1371/journal.pone.0216997  
18  
19  
20 54. Olsen SN, Wronski A, Castano Z, et al. Loss of RasGAP Tumor Suppressors Underlies the  
21 Aggressive Nature of Luminal B Breast Cancers. *Cancer Discov* 2017;7(2):202-17. doi:  
22 10.1158/2159-8290.CD-16-0520  
23  
24  
25 55. Stover DG, Parsons HA, Ha G, et al. Association of Cell-Free DNA Tumor Fraction and Somatic  
26 Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. *J Clin*  
27 *Oncol* 2018;36(6):543-53. doi: 10.1200/JCO.2017.76.0033  
28  
29  
30 56. Gibson CJ, Fell G, Sella T, et al. Clonal Hematopoiesis in Young Women Treated for Breast  
31 Cancer. *Clin Cancer Res* 2023;29(13):2551-58. doi: 10.1158/1078-0432.CCR-23-0050  
32  
33  
34 57. Goddard ET, Hill RC, Nemkov T, et al. The Rodent Liver Undergoes Weaning-Induced Involution  
35 and Supports Breast Cancer Metastasis. *Cancer Discov* 2017;7(2):177-87. doi: 10.1158/2159-  
36 8290.CD-16-0822  
37  
38  
39 58. Rocca WA, Gazzuola-Rocca L, Smith CY, et al. Accelerated Accumulation of Multimorbidity After  
40 Bilateral Oophorectomy: A Population-Based Cohort Study. *Mayo Clin Proc* 2016;91(11):1577-  
41 89. doi: 10.1016/j.mayocp.2016.08.002  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Figure Legends**  
4  
5  
6

7 **Figure 1. Overview of YWS data and biospecimen collection**  
8

9 YWS, Young Women's Breast Cancer Study  
10  
11  
12

13 **Figure 2. YWS Study Flow Diagram**  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1. Demographic Characteristics**

	N (%)
<b>Age at diagnosis</b>	
<25	25 (2)
25-30	139 (11)
31-35	352 (27)
36-40	780 (60)
<b>Race</b>	
American Indian /Alaska Native	6 (<1)
Asian	88 (7)
Native Hawaiian/Other Pacific Islander	0 (0)
Black or African American	48 (4)
White	1101 (85)
More than one race	16 (1)
Unknown or not reported	38 (3)
<b>Ethnicity</b>	
Hispanic	56 (4)
Non-Hispanic	1045 (81)
Unknown or not reported	196 (15)

**Table 2. Disease/tumor characteristics and BRCA mutation status (N=1297)**


	N (%)
<b>Stage</b>	
0	98 (8)
I	413 (32)
II	525 (41)
III	197 (15)
IV	64 (5)
<b>Bilateral breast cancer</b>	21 (2)
<b>Tumor grade</b>	
1	89 (7)
2	445 (34)
3	752 (58)
Missing/Unknown	11 (0.9)
<b>ER status</b>	
Positive	945 (73)
Negative	351 (27)
Missing/Unknown	1 (<1)
<b>PR status</b>	
Positive	848 (65)
Negative	441 (34)
Missing/Unknown	8 (<1)
<b>HER2 status</b>	
Positive	360 (28)
Negative	880 (68)
Missing/Unknown/Not performed*	57 (4)
<b>Subtype</b>	
Luminal A-like	395 (31)
Luminal B-like	269 (21)
Luminal B/HER2	255 (20)
HER2-enriched (ER-, PR-, HER2+)	105 (8)
Triple negative	210 (16)
Missing/Unknown	63 (5)
<b>BRCA mutation status</b>	
BRCA1+	90 (7)
BRCA2+	54 (4)
Variant of unknown significance	54 (4)
No mutation detected	919 (71)
Not tested or unknown testing status	180 (14)

\*Missing/Unknown subtype includes cases of DCIS for which HER2 was not performed

**Table 3. Summary of Primary Survey Domains and Schedule, Baseline through Year 15**


	Survey Schedule																		
	Baseline	Month						Year											
		6	12	18	24	30	3	4	5	6	7	8	9	10	11	12	13	14	15
<b>Socio-demographics including insurance, finances</b>	X		X		X		X	X	X	X	X	X	X	X	X	X	X	X	X
<b>Medical/ Family History</b>	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
<b>Genetics</b>			X		X		X		X		X		X						
<b>Health-related Activities/Social History</b>	X		X		X		X	X	X	X	X	X	X						
<b>Fertility/Gynecologic</b>	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
<b>Lactation Assessment</b>	X		X		X		X		X		X	X	X	X	X	X	X	X	X
<b>Contraception</b>									X		X								
<b>QOL/Anxiety/Depression</b>	X	X	X		X		X	X	X		X			X					X
<b>Coping</b>		X		X															
<b>Fear of Recurrence</b>	X		X		X		X	X	X		X			X					X
<b>Menopausal Symptoms</b>	X	X	X		X		X	X	X		X			X					X
<b>Social Support</b>	X		X		X		X	X	X										
<b>Spirituality Assessment</b>	X						X												
<b>Treatment Decisions</b>		X																	
<b>Medications List</b>	X		X		X		X	X	X	X	X	X	X	X					X
<b>Tamoxifen Adherence</b>						X													
<b>Healthcare Utilization</b>											X								X

Figure 1



peer review only

Figure 2.



1  
2  
3 **SUPPLEMENTAL MATERIAL**  
4  
5

6 **Cohort profile: Helping Ourselves, Helping Others - The Young Women's Breast Cancer Study**  
7 **(YWS): A multi-site prospective cohort study to advance the understanding of breast cancer**  
8 **diagnosed in women aged 40 and younger**  
9

10  
11 **Supplemental Tables: 2**  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



**Supplemental Table 1. YWS enrollment sites**

Site	State/Country	Number Enrolled
Dana-Farber Cancer Institute/Brigham and Women's Hospital <sup>a</sup>	MA	669
Beth Israel Deaconess Medical Center <sup>a</sup>	MA	50
Cape Cod Hospital <sup>b</sup>	MA	19
Faulkner Hospital <sup>a</sup>	MA	47
Lowell General Hospital <sup>b</sup>	MA	11
Massachusetts General Hospital <sup>a</sup>	MA	256
Mayo Clinic <sup>a</sup>	MN	35
Milford Hospital <sup>b</sup>	MA	1
Newton-Wellesley Hospital <sup>b</sup>	MA	30
North Shore Cancer Center (Salem) <sup>b</sup>	MA	21
South Shore Hospital <sup>b</sup>	MA	9
Sunnybrook Health Sciences <sup>a</sup>	Canada	62
University of Colorado Hospital <sup>a</sup>	CO	92

<sup>a</sup>academic sites <sup>b</sup>community sites

YWS, Young Women's Breast Cancer Study; MA, Massachusetts; MN, Minnesota; CO, Colorado

Supplemental Table 2. YWS Blood Specimens Collected

Number of Collections	Patients (N)	Baseline	1 year	4 year
1 Timepoint	N=71			
	N=137			
	N=23			
2 Timepoints	N=247			
	N=44			
	N=132			
3 Timepoints	N=471			
<b>Total/Timepoint</b>		N=833	N=987	N=670

# BMJ Open

## Cohort profile: Helping Ourselves, Helping Others - The Young Women's Breast Cancer Study (YWS): A multi-site prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 and younger

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-081157.R2
Article Type:	Cohort profile
Date Submitted by the Author:	01-May-2024
Complete List of Authors:	Rosenberg, Shoshana M. ; Dana-Farber Cancer Institute, Medical Oncology; Weill Cornell Medicine, Population Health Sciences Zheng, Yue; Dana-Farber Cancer Institute, Data Science Ruddy, Kathryn; Mayo Clinic, Medical Oncology Poorvu, Philip D.; Dana-Farber Cancer Institute, Medical Oncology Snow, Craig; Dana-Farber Cancer Institute, Medical Oncology Kirkner, Gregory J.; Dana-Farber Cancer Institute, Medical Oncology Meyer, Meghan E.; Dana-Farber Cancer Institute, Medical Oncology Tamimi, Rulla M. ; Weill Cornell Medical College, Population Health Sciences Schapira, Lidia; Stanford University, Department of Medicine, Division of Medical Oncology Peppercorn, Jeffrey; Massachusetts General Hospital, Department of Medicine, Division of Medical Oncology Come, Steven; Beth Israel Deaconess Medical Center, Medical Oncology Borges, Virginia; University of Colorado Denver, Medical Oncology Warner, Ellen; Sunnybrook Health Sciences Centre, Medical Oncology Gelber, Shari; Dana-Farber Cancer Institute, Medical Oncology Collins, Laura; Beth Israel Deaconess Medical Center, Pathology Winer, Eric P.; Dana-Farber Cancer Institute, Medical Oncology; Yale University Yale Cancer Center Partridge, Ann; Dana-Farber Cancer Institute, Medical Oncology
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Patient-centred medicine
Keywords:	ONCOLOGY, Breast tumours < ONCOLOGY, Quality of Life

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Cohort profile: Helping Ourselves, Helping Others - The Young Women's Breast Cancer Study**  
4  
5 **(YWS): A multi-site prospective cohort study to advance the understanding of breast cancer**  
6  
7 **diagnosed in women aged 40 and younger**  
8  
9

10  
11 Shoshana M. Rosenberg,<sup>1,2,3</sup> Yue Zheng,<sup>4</sup> Kathryn J. Ruddy,<sup>5</sup> Philip D. Poorvu,<sup>2,3</sup> Craig Snow,<sup>2,3</sup>  
12  
13 Gregory J. Kirkner,<sup>2,3</sup> Meghan E. Meyer,<sup>2,3</sup> Rulla M. Tamimi,<sup>1</sup> Lidia Schapira,<sup>6</sup> Jeffrey Peppercorn,<sup>7</sup>  
14  
15 Steven Come,<sup>8</sup> Virginia F. Borges,<sup>9</sup> Ellen Warner,<sup>10</sup> Shari Gelber,<sup>2,3</sup> Laura C. Collins,<sup>11</sup> Eric P.  
16  
17 Winer,<sup>2,3,12</sup> and Ann H. Partridge<sup>2,3</sup>  
18  
19

20  
21  
22  
23 <sup>1</sup>Population Health Sciences, Weill Cornell Medicine, New York, NY, USA (current affiliation); <sup>2</sup>Medical  
24  
25 Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; <sup>3</sup>Breast Oncology Program, Dana-Farber  
26  
27 Brigham Cancer Center, Boston, MA, USA; <sup>4</sup>Data Science, Dana-Farber Cancer Institute, Boston, MA,  
28  
29 USA; <sup>5</sup>Medical Oncology, Mayo Clinic, Rochester, MN, USA; <sup>6</sup>Department of Medicine, Division of  
30  
31 Medical Oncology, Stanford University, Stanford, CA, USA; <sup>7</sup>Department of Medicine, Division of Medical  
32  
33 Oncology, Massachusetts General Hospital, Boston MA, USA; <sup>8</sup>Medical Oncology, Beth Israel  
34  
35 Deaconess Medical Center, Boston, MA, USA; <sup>9</sup>Medical Oncology, University of Colorado Anschutz  
36  
37 Medical Campus, Aurora, CO, USA; <sup>10</sup>Department of Medicine, Division of Medical Oncology, Odette  
38  
39 Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; <sup>11</sup>Pathology, Beth Israel  
40  
41 Deaconess Medical Center, Boston, MA, USA; <sup>12</sup>Yale Cancer Center, New Haven, CT, USA (current  
42  
43 affiliation)  
44  
45

46  
47 **Corresponding author:**  
48

49  
50 Ann H. Partridge

51  
52 Dana-Farber Cancer Institute

53  
54 450 Brookline Avenue  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Boston, MA 02067

Tel: 617-632-3800

Email: [ann\\_partridge@dfci.harvard.edu](mailto:ann_partridge@dfci.harvard.edu)

**Word count:** 3880

**Figures:** 2

**Tables:** 3

**Supplemental tables:** 2

**Keywords:** young women; breast cancer; outcomes; cohort study

For peer review only

## **Abstract**

**Purpose:** Compared to older women diagnosed with breast cancer, younger women are more likely to die of breast cancer and more likely to suffer psychosocially in both the short and long-term. The Young Women's Breast Cancer Study (YWS) is a multisite prospective cohort study established to address gaps in our knowledge about this vulnerable and understudied population.

**Participants:** The YWS enrolled 1,302 women newly diagnosed with stage 0-IV breast cancer at age 40 years or younger at 13 academic and community sites in North America between 2006 and 2016. Longitudinal patient-reported outcome data are complemented by clinical data abstraction and biospecimen collection at multiple time-points.

**Findings to Date:** Key findings related to fertility include that nearly 40% of participants were interested in pregnancy following diagnosis; of those who reported interest, 10% pursued fertility preservation. Overall, approximately 10% of YWS participants became pregnant in the first 5 years after diagnosis; follow-up is ongoing for pregnancies after 5 years. Studies focused on psychosocial outcomes have characterized quality of life, post-traumatic stress, and fear of recurrence, with findings detailing the factors associated with the substantial psychosocial burden many young women face during and following active treatment. Multiple studies have leveraged YWS biospecimens, including whole exome sequencing of tumor analyses that revealed that select somatic alterations occur at different frequencies in young (age <35) versus older women with luminal A breast cancer, and a study that explored clonal hematopoiesis of indeterminate potential found it to be rare in young survivors.

**Future Plans:** With a median follow-up of approximately 10 years, the cohort is just maturing for many relevant long-term outcomes and provides outstanding opportunities to further study and build collaborations to address gaps in our knowledge, with the ultimate objective to improve care and outcomes for young women with breast cancer.

**Registration:** [clinicaltrials.gov](https://clinicaltrials.gov), NCT01468246

### **Strengths and Limitations**

- Established in 2006, the Young Women's Breast Cancer Study (YWS) is a multi-site, prospective cohort of women with young onset breast cancer.
- The YWS was designed to conduct regular medical record review and collect biospecimens and serial patient-reported outcomes.
- Eligibility criteria included: 1) female; 2) a new diagnosis of stage 0-IV breast cancer 3) age  $\leq 40$  years at diagnosis; and 4) ability to understand written and spoken English.
- Robust follow-up procedures optimize participant engagement and ensure accurate ascertainment of oncologic outcomes and vital status.
- Recruitment was hospital-based and may not be truly representative of the general population, potentially impacting generalizability.



## Introduction

Greater than 14,000 women aged 40 years and younger are diagnosed with breast cancer annually in the United States alone, with thousands more worldwide. Far less is known, however, about breast cancer in younger vs. older women. Further, recent population-based data have demonstrated that the incidence of breast cancer is growing in this population.[1,2] Breast cancer is the leading cause of cancer-related deaths in women under 40 years of age, and while improved over time, survival rates for young women with breast cancer remain lower compared to older women.[3,4] The reasons for the poorer outcomes experienced by young women as understood to date are complex and multifactorial. Compared to older women, young women are more likely to present with symptoms and at a more advanced stage, due in part to diagnostic delays and lack of screening in this population.[5,6] Breast cancers arising in young women tend to have more unfavorable pathologic features and aggressive subtypes, including greater proportions with luminal B, HER2-positive, or triple-negative disease.[7,8] Young women are at high risk of non-adherence to risk reducing adjuvant hormonal therapy.[9-11] Compounding their disparate disease outcomes, young breast cancer survivors may be at greater risk of long-term or late morbidity given the aggressive therapy that they usually receive and anticipated long life trajectory in survivorship, although there are limited data in this area.

Of particular significance are the variety of young age-related medical and psychosocial issues that this population faces as a result of their diagnosis and treatment, which contribute to a greater risk of psychosocial distress compared to older patients.[12] These issues include hereditary predisposition and risks of future cancer, sexual dysfunction, infertility, premature menopause, body image concerns, role functioning including parenting, career and schooling disruption and the development of short- and long-term comorbidities. Collectively, these problems may influence treatment decisions, as well as disease and psychosocial outcomes.

## ***Purpose of the Young Women's Breast Cancer Study***

Young women are underrepresented in large prospective cohorts as well as in randomized trials evaluating novel therapies and prognostic tools to guide breast cancer treatment decisions.[13-15] Hesitancy to extrapolate data from studies of primarily older populations may result in young women being excluded or delayed in benefits from treatment improvements, or put at risk for overtreatment based solely on young age. Even in large prospective cohort studies and clinical trials inclusive of premenopausal women, as well as in population-based registries, there are rarely enough young women and/or adequate granularity of data to draw meaningful conclusions for this subpopulation. For example, the Nurses' Health Studies have previously reported 374 incident cases age <40 years (vs. 2,533 cases in women age ≥40),[16] the Black Women's Health Study had 529 cases of breast cancer diagnosed at age <45 years documented through 2013 (vs. 1,534 cases in women aged 45 and older),[17] and the Suppression of Ovarian Function Trial had 933 participants age <40 years at diagnosis,[18] with limited details in follow-up for most. The Young Women's Breast Cancer Study (YWS) was designed to address gaps in knowledge regarding breast cancer in younger women, including unanswered questions pertaining to diagnosis and presentation, underlying disease biology, optimal treatment, survivorship, psychosocial issues, and living with metastatic disease. The YWS is the first and one of the largest cohorts of women with young onset breast cancer designed to conduct regular medical record review and collect biospecimens and patient-reported outcomes (PROs) (**Figure 1**). The original study objectives were to 1) enroll a cohort of women age ≤40 years newly diagnosed with breast cancer; 2) characterize the cohort at diagnosis and in follow-up regarding disease and psychosocial outcomes; and 3) archive tumor and blood specimens for future studies.

## **Cohort Description**

### ***Overview***

From 2006-2016, the YWS enrolled 1,302 women from 13 North American academic and community sites (**Supplemental Table 1**). There was high accrual of those approached for enrollment

1  
2  
3 (1302/2186, 60% participate rate). Four patients were determined to be ineligible, and one withdrew  
4 consent following enrollment leaving 1,297 women who are followed. Reasons for non-participation are  
5 detailed in **Figure 2**. The YWS is approved by the Institutional Review Board at Dana-Farber Harvard  
6 Cancer Center (DF/HCC) and other participating sites.  
7  
8  
9  
10

### 11 12 **Enrollment procedures**

13  
14 At Massachusetts sites, potentially eligible participants were systematically identified by  
15 pathology review or by pathology or clinic list review by a research nurse on a monthly or bi-monthly  
16 basis. The Dana-Farber Cancer Institute (DFCI) Survey and Data Management Core then reviewed the  
17 medical record to confirm eligibility. At sites outside of Massachusetts, study staff assisted with  
18 recruitment via systematic review of patient lists. Eligibility was confirmed prior to inviting. Inclusion  
19 criteria included: 1) female; 2) a new diagnosis of stage 0-IV breast cancer 3) age  $\leq$ 40 years at  
20 diagnosis; and 4) ability to understand written and spoken English to the extent necessary to complete  
21 the questionnaires. Participants enrolled a median of 4 (range: 0-29) months following diagnosis.  
22 Following receipt of written informed consent, participants were mailed a welcome letter, medical record  
23 release form, tumor specimen request form, and the baseline survey. Current median follow-up of the  
24 cohort is 10 years (range: 0.4-16 years). Because calculation of follow-up is based on individual patient  
25 data, the lower end of this range (e.g., 0.4 years) reflects the follow-up duration of patients who died  
26 soon after diagnosis and/or were lost to follow-up early in the study.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **Participant characteristics**

44  
45 **Table 1** includes a summary of YWS participant age at diagnosis, race, and ethnicity. Baseline  
46 survey questions asked participants about their race and ethnicity. For baseline survey non-responders  
47 or instances where this information was not reported, race/ethnicity as determined from medical record  
48 at screening/enrollment was used. Approximately 14% of YWS participants are from a non-White  
49 and/or Hispanic racial/ethnic background. Median age at diagnosis was 36 (range: 17-40) years. Key  
50 cancer information including stage, grade, subtype, and BRCA mutation status is detailed in **Table 2**.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Recognizing that there have been changes in how we measure social determinants of health since the  
4 baseline survey was developed and to make these data more complete, we are sending YWS  
5 participants a supplemental survey including updated questions regarding race, ethnicity, gender, and  
6 sexual identity.  
7  
8  
9  
10

### 11 ***Patient and Public Involvement***

12  
13  
14 Since the study's inception, we have invited patient volunteers and patient advocates to review  
15 survey content as well as assist with strategies to communicate results to YWS participants and other  
16 young patients. We routinely share lay summary results from YWS analyses directly through the DFCI  
17 Program for Young Adults with Breast Cancer newsletter as well as intermittent webinars and patient  
18 forums. Newsletters and webinars are also archived on the program's public website  
19 (<https://youngandstrong.dana-farber.org>).  
20  
21  
22  
23  
24  
25  
26  
27

### 28 ***YWS Data Collection and Follow-up***

29  
30  
31 *Surveys:* Participants completed surveys at study baseline (median of 5 months post-diagnosis), 6  
32 months after enrollment, and 1-year post-diagnosis. Participants were then surveyed every 6 months  
33 through 3 years, and annually thereafter. Participants enrolled at the Toronto site (N=62) are sent  
34 abbreviated ("short-form") surveys that ask for socio-demographics, how their breast cancer presented,  
35 fertility and gynecologic information, and cancer endpoints. At the 10-year timepoint, Toronto  
36 participants are sent a full survey to complete. A smaller subset of participants (N=29) who enrolled at  
37 other sites chose to complete the short-form follow-up annual surveys that only ask about fertility,  
38 gynecologic and cancer outcomes. For the initial 7 years of the YWS, all surveys were mailed to main  
39 study participants; participants completing short-form surveys were given the option of completing  
40 surveys on paper or online via Survey Monkey. Beginning at the 8-year survey time point, participants  
41 were offered the option to complete an electronic survey through REDCap. In March 2020, due to  
42 COVID restrictions limiting the ability to mail materials, participants with a valid email address (98%)  
43 were sent surveys through REDCap. Collectively, these surveys have yielded an unparalleled resource  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 of longitudinal PRO data related to menopausal status, fertility, anxiety, depression, quality of life  
4 (QOL), fear of recurrence, treatment side-effects, employment, genetics, and treatment decision-  
5 making (see **Table 3** for domains/timeline for the first 15 years of follow-up). We also periodically invite  
6 participant subsets to complete supplemental surveys to investigate salient issues in greater detail.[19-  
7 24]

8  
9  
10  
11  
12  
13 *Follow-up to optimize survey response rates:* A research coordinator systematically contacts  
14 participants who do not complete their surveys with a phone call at 3 weeks after the initial survey is  
15 sent out; the survey is re-sent at 6 weeks if the participant has still not completed the survey at that  
16 timepoint. Additional calls and/or survey resends are then conducted monthly up to 6 months following  
17 the initial send out, as needed. Response rates (surveys received/surveys sent) for the majority of  
18 survey time points range from 86%-91%. Response rates for 7 and 10-year surveys are modestly lower  
19 (71% for 7-year and 65% for 10-year) due to our attempt to re-engage non-responding participants at  
20 those timepoints.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 *Medical Records:* Medical records through the first 18 months following diagnosis are available for  
32 100% of participants. Records are also reviewed at additional timepoints (including at 10 years) to 1)  
33 confirm and collect specifics on cancer outcomes (recurrences, new primary breast cancers, other  
34 cancers) that are self-reported on surveys; and 2) to update comorbidities including recurrences and  
35 new cancers and vital status among participants who do not regularly complete surveys. We have  
36 abstracted initial treatment information, including specific chemotherapy regimens started and received,  
37 surgery, radiation, genetic testing (panel type and results), and co-morbidities using the Charlson  
38 framework[25,26] from the medical record to validate/supplement what patients report on surveys, and  
39 to fill in missing data.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 *Ascertainment of Cancer Outcomes and Vital Status:* Recurrences, new primary breast cancers, and  
51 new (non-breast) cancers are assessed on each survey. In addition to site(s) of recurrence or new  
52 cancer, participants are asked to report the date of the recurrence. Any self-report of a recurrence or  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 new cancer, including site and date (either radiologic or pathologic confirmation) is confirmed by  
4 medical record review. Because this process relies on survey responses to ascertain outcomes, for  
5 those participants who are no longer responding to surveys we request and review updated medical  
6 records for these patients every 4 years. For participants treated at DFCI, Brigham and Women's  
7 Hospital, Massachusetts General Hospital or an affiliate network site, the National Death Index is  
8 queried periodically to obtain vital status information. Following the 2018-2019 update, we were able to  
9 ascertain oncologic outcomes and vital status for 321 patients who were survey non-responders. As of  
10 September 2023, among the entire cohort, we have documented 181 participants with distant  
11 metastatic recurrences, 96 participants with locoregional recurrences, 22 participants with new primary  
12 breast cancers, and 49 participants with new non-breast primary cancers, and 186 deaths.

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24 *Tissue Specimen Collection/Storage:* Pathology reports, hematoxylin and eosin (H&E) stained slides,  
25 and a representative paraffin block of tumor were requested from the institution where the patient had  
26 her surgery; the patient's signed release for the specimens and reports were sent to the pathology  
27 department. A YWS study pathologist reviewed each pathology report and an H&E stained section of  
28 the tumor block to annotate tumor details.[8,27] Slides from the core needle biopsy were requested as  
29 well as from the surgery in neoadjuvant therapy cases. Hormone and HER-2/neu (HER2) receptor  
30 expression, and lymph node status, were extracted from the pathology reports. Of 1297 participants  
31 followed, 1278 (99%) consented to providing a tumor specimen for review. Primary tumor pathology  
32 has been centrally reviewed on 97% of patients (1242/1278), with blocks (N=1120) and cores for the  
33 tissue microarray (N=21) from tumor specimens collected on 1141 patients (88%). Currently, there are  
34 1370 specimens from 1242 patients available in the tissue microarray blocks (patients who received  
35 neoadjuvant therapy may have more than one block).

36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50 *Blood Collection/Storage:* Blood is collected at three timepoints (two 10mL tubes of whole blood at  
51 each timepoint), each with a several month "window" to maximize our ability to collect blood while  
52 minimizing burden: baseline (enrollment up to 9 months post-diagnosis); 1-year (9 months-2 years  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 post-diagnosis); and 4-year (3.5 – 5 years post diagnosis). Overall, 94% (1224/1297) of participants  
4 consented to blood collection. Of these, there is at least one sample available from 92% of participants,  
5 with 73% of participants providing samples at two or more time points (**Supplemental Table 2**).

6  
7  
8  
9 Women were asked to go to their treating institution or a local laboratory with the materials provided in  
10 the blood specimen kit, unless drawn at DFCI where kits are provided on site by staff. Specimens were  
11 processed at the DFCI Breast Cancer CORE Blood Repository, where whole blood (4 aliquots/2ml  
12 each) and plasma (2 aliquots/2mL each) were isolated and banked for future studies.

### 13 14 15 16 17 18 **Findings to Date**

19  
20  
21 Since its inception, YWS investigations have characterized more fully the experience of breast  
22 cancer in young women, creating a platform from which to study molecular and biologic issues, as well  
23 as the health and psychosocial repercussions of a breast cancer diagnosis and treatment at a young  
24 age. As the YWS has matured, we have expanded our investigations to include collaborations with  
25 basic and translational scientists enabling us to address new questions, advancing knowledge of the  
26 biology of the disease as well as to improve clinical care and outcomes. In addition, research findings  
27 from the YWS have informed international guidelines and clinical practice.[28,29]

### 28 29 30 31 32 33 34 35 36 ***Fertility Issues and Pregnancy***

37  
38  
39 In 2014, we published findings from the baseline survey regarding fertility concerns and fertility  
40 preservation strategies used.[30] Since then, additional publications from the YWS have described  
41 breast cancer diagnosed during pregnancy,[31] pregnancy after breast cancer,[32] treatment-related  
42 amenorrhea,[33] fertility concerns and endocrine therapy decision-making,[34] and fertility concerns in  
43 germline genetic carriers.[35] Key findings included the observation that nearly 40% of participants  
44 were interested in pregnancy after breast cancer; of those interested, 10% pursued fertility preservation  
45 strategies.[30] Another study documented that approximately 20% of women become amenorrheic in  
46 survivorship after standard chemotherapy, with variability by chemotherapy type and age.[33] A third  
47 study evaluated post-diagnosis pregnancies, observing that 10% became pregnant in the first 5 years

1  
2  
3 after breast cancer.[32] Fertility outcomes remain a primary outcome of interest in continued follow-up  
4 of the cohort and the rich and detailed fertility and gynecologic data collected at each time point will  
5 allow for novel and detailed investigations regarding impact of pregnancy on cancer endpoints, and  
6 menopausal and related comorbidity outcomes. Findings from this work have been referenced in  
7 international guidelines[28,29] and informed an international trial that evaluated the safety of pregnancy  
8 after breast cancer.[36] We are also participating in an international, multi-site, retrospective cohort  
9 study (PI: Dr. Matteo Lambertini, University of Genoa, IT) inclusive of >1400 patients with BRCA+  
10 breast cancer from 30 sites across North America, Europe, Latin America, and Israel, contributing  
11 clinical, genetic, and PRO data on 125 YWS participants with BRCA mutations. To date, there have  
12 been two major publications reporting analyses of pregnancy outcomes as well as clinical outcomes  
13 from this collaboration.[37,38]

### ***Systemic Treatment and Disease Recurrence and Response***

14  
15 In 2017, we conducted a study examining the prognostic value of genomic expression prediction  
16 assays in the YWS. Prior research that led to the routine incorporation of such tools into clinical care  
17 had included relatively few women <40 years old, resulting in hesitation among providers to use them  
18 for young women. We demonstrated that Recurrence Score (RS) was prognostic and appeared to be  
19 predictive of chemotherapy benefit or lack thereof in patients with node-negative disease.[39] These  
20 data have informed recent guidelines and clinical practice supporting the use of RS in young patients to  
21 influence chemotherapy decisions.[28] We subsequently demonstrated the association of RS with  
22 pathologic complete response (pCR) after neoadjuvant chemotherapy for hormone receptor-positive  
23 disease[40]; results from this study are providing preliminary data for planned correlative work in a pre-  
24 operative clinical trial in the Alliance for Clinical Trials in Oncology.

### ***Psychosocial Implications of Breast Cancer in Young Women***

25  
26 A large focus of the YWS has been to study the early psychological and social repercussions of  
27 breast cancer in young women to identify areas for tailored support and management strategies. We



1  
2  
3 have characterized sexual functioning and body image issues, the impact of a diagnosis on  
4 employment, post-traumatic stress, fear of recurrence, anxiety and depression in women with de novo  
5 stage IV disease, as well as the impact of the diagnosis on the partners of YWS participants.[41-48]  
6  
7 Recent studies have found that more extensive surgery and radiation are associated with poorer  
8 QOL[21,49] as well as increased arm morbidity.[50] Collectively, our findings indicate that young  
9 women experience a substantial psychosocial burden during and following the completion of active  
10 treatment, and this burden is associated with certain patient, disease and treatment variables which can  
11 be targeted for intervention.  
12  
13  
14  
15  
16  
17  
18  
19  
20

### 21 ***Biological Differences in Breast Cancer by Age***

22  
23 Collaborative efforts have yielded important findings to date including a comparison of whole  
24 exome sequencing profiles of the youngest 100 participants ( $\leq 35$  years at diagnosis) to older women  
25 from The Cancer Genome Atlas (TCGA).[51,52] This analysis revealed that somatic alterations in three  
26 genes (*PIK3CA*, *GATA3*, and *ARID1A*) occur at different frequencies in young versus older women with  
27 luminal A breast cancer.[52] Additional investigation of these genes could delineate biological  
28 susceptibilities for young patients. Several additional studies have used or pooled tissue and/or blood  
29 specimens including a genome wide association study characterizing single nucleotide polymorphisms  
30 in young patients,[53] a study of RasGAP genes in luminal B tumors,[54] and a study of somatic  
31 mutations in patients with metastatic triple negative breast cancer,[55] and the development of a test to  
32 identify minimal residual disease in early-stage breast cancer.[51] Most recently, we used novel DNA  
33 sequencing methods to evaluate the prevalence and mutation spectrum of clonal hematopoiesis in  
34 young women and its association with patient and treatment characteristics and outcomes.[56]  
35  
36 Reassuringly, clonal hematopoiesis of indeterminate potential (CHIP) was rare, with a prevalence of  
37 <3% among the 878 women in the analytic cohort.[56] The YWS has also provided clinical data  
38 detailing cancer outcomes of nulliparous vs. recently parous women, for an analysis supporting the  
39 novel pre-clinical finding that weaning-induced liver involution establishes a pro-metastatic  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 microenvironment, a potential explanation for more poor cancer outcomes of recently parous  
4 women.[57] Several analyses to understand the biologic underpinnings of early onset breast cancer are  
5 underway.  
6  
7  
8  
9

### 10 11 **Collaboration**

12  
13 The YWS is uniquely positioned for investigations of age-related tumor and host biology as well  
14 as studies evaluating the impact of hereditary predisposition, post-diagnosis pregnancy, premature  
15 menopause, psychosocial, lifestyle and care delivery on cancer endpoints and comorbidities. The YWS  
16 research team includes medical, surgical, and radiation oncologists, epidemiologists, pathologists, and  
17 biostatisticians, and our collaborations have grown to include experts in cancer genomics, biology,  
18 tumor microenvironment, and behavioral health. While data are not publicly available, investigators  
19 interested in accessing YWS-generated data and/or biospecimens should contact the Principal  
20 Investigator (A. Partridge) and submit a request to the DF/HCC breast users committee  
21 ([https://www.dfhcc.harvard.edu/research/research-programs/clinical-based-programs/breast-](https://www.dfhcc.harvard.edu/research/research-programs/clinical-based-programs/breast-cancer/program-resources/dfhcc-breast-users-committee/)  
22 [cancer/program-resources/dfhcc-breast-users-committee/](https://www.dfhcc.harvard.edu/research/research-programs/clinical-based-programs/breast-cancer/program-resources/dfhcc-breast-users-committee/)).  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Future Directions**

36  
37 The YWS has proven to be a rich scientific resource that has resulted in impactful research that  
38 has advanced our understanding of breast cancer in young women, generated new lines of  
39 investigation, and informed clinical guidelines. Breast cancer is the leading cause of cancer-related  
40 deaths in young women, and while improved over time, survival rates for young women with breast  
41 cancer remain lower compared to older women.[3,4] Thus, identifying risk factors for these poorer  
42 outcomes in younger women is critical. With the cohort maturing, we expect the number of recurrent  
43 disease events expected to increase by ~50% over the next 5 years and beyond, allowing for further  
44 evaluation of predictors of oncologic outcomes, including breast cancer free survival and overall  
45 survival. With relatively large numbers of young patients treated with contemporary regimens and well-  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 annotated treatment details, we will be well-positioned to evaluate the impact of post-diagnosis  
4 pregnancies on recurrence, new primary cancer, or death, assessment of risk factors for second  
5 cancers by breast cancer phenotype and germline pathogenic variant status, as well as risk factors for  
6 late recurrences among women diagnosed at a young age. Studies of the role of ctDNA on predicting  
7 late recurrence and exploring tumor and host characteristics that may be conducive to  
8 recurrence/disease resistance to therapy in young women (e.g., tumor immune microenvironment  
9 differences by recent parity status at diagnosis) have great potential.  
10  
11  
12  
13  
14  
15  
16  
17

18 As a survivorship cohort, evaluating long-term, late effects of breast cancer treatment and  
19 survivorship is a central objective of the YWS. A critical charge of cancer survivorship research is  
20 identifying potentially modifiable factors that predict these risks. Young breast cancer survivors may be  
21 at high risk of long-term or late morbidity given the aggressive therapy they usually receive and  
22 anticipated long life trajectory after the cancer. Additionally, they may have hereditary, behavioral, and  
23 comorbidity predispositions to disease. The concerns unique to or accentuated by their stage of life at  
24 diagnosis also appear to contribute to the increased risk of psychological distress seen in this age  
25 group both at diagnosis and in long-term follow-up.[12] With a median follow-up of 10 years, we are  
26 now well-poised to study late and long-term morbidity, including premature menopause (age <45  
27 years), which in non-cancer populations is associated with substantial multimorbidity including  
28 increased risk of depression, hyperlipidemia, heart disease, asthma, chronic obstructive pulmonary  
29 disease, arthritis and osteoporosis.[58] On each survey, YWS participants are asked about their  
30 menstrual status, including date of last menstrual period, reasons for periods stopping, as well as  
31 questions about gynecologic procedures providing granular data to inform analyses. Given the current  
32 age of the cohort, the next several years are a critical time to conduct in-depth assessment of the  
33 menopausal transition among women who remained premenopausal following treatment, including  
34 timing, risk factors for premature menopause, and the impact of early menopause on QOL and  
35 comorbidities in this population. This data resource will also facilitate investigations ranging from health  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 care utilization assessments, changes in lifestyle factors over time, and trajectories of QOL, to  
4  
5 evaluations of the association of specific co-morbidities (e.g., heart disease, diabetes) with premature  
6  
7 menopause, weight gain, body composition, metabolic biomarkers, inflammatory mediators, hormone  
8  
9 levels, and biomarkers of accelerated aging.  
10

### 11 12 13 14 15 **Strengths and Limitations**

16  
17 With a repository of biospecimens, clinical data, and serial PRO collection, the YWS is a robust  
18  
19 platform from which to study molecular and biologic issues, as well as the health and psychosocial  
20  
21 repercussions of a breast cancer diagnosis and treatment in young women. One of the core strengths  
22  
23 of the YWS is high participant engagement, which has facilitated our ability to follow participants for  
24  
25 both medical and psychosocial outcomes in extended follow-up. Additionally, we have leveraged the  
26  
27 collection of blood specimens at three time points – baseline, 1 year, and 4 years after diagnosis – for  
28  
29 novel investigations that are complemented with clinical data that have been systematically abstracted  
30  
31 from the medical record. However, as the YWS is an observational cohort study, establishing causality  
32  
33 vs. association can be challenging and there is a risk of unmeasured or unaccounted for confounders in  
34  
35 analyses. As the main objective of the YWS was to establish a survivorship cohort that followed young  
36  
37 women diagnosed with breast cancer, women older than 40 and women without a history of cancer  
38  
39 were not enrolled; thus, our study is not designed to enable cross-age comparisons or comparisons  
40  
41 with non-cancer, age-matched “controls.” Additionally, while the YWS is a multi-site study that included  
42  
43 both academic and community sites, women enrolled in the YWS are predominantly white, non-  
44  
45 Hispanic, and highly educated, which may impact generalizability of findings to young breast cancer  
46  
47 survivors from more diverse racial, ethnic, and socio-economic backgrounds. Acknowledging this  
48  
49 limitation, more recent studies conducted by our team, including intervention trials informed by YWS  
50  
51 findings, have focused efforts to improve outreach to patients from historically under-represented racial  
52  
53 and ethnic groups.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Data availability statement:** Requests to access YWS data/biospecimens should be made to the  
4 Principal Investigator, Dr. Ann Partridge ([ann\\_partridge@dfci.harvard.edu](mailto:ann_partridge@dfci.harvard.edu)).

5  
6  
7 **Acknowledgements:** We thank all participants for their past and continued contributions to the YWS  
8 study. We also thank Ms. Kate Bifolck for editorial and submission assistance; she is a full-time  
9 employee of Dana-Farber Cancer Institute.

10  
11  
12  
13  
14 **Funding:** Susan G. Komen (SAC100008, Partridge) and Breast Cancer Research Foundation (BCRF-  
15 21-124, Partridge)

16  
17  
18 **Ethics statements:** The YWS is approved by the Institutional Review Board at Dana-Farber Harvard  
19 Cancer Center (IRB# 06-169) and other participating sites. Participants provided written informed  
20 consent at the time of enrollment.

21  
22  
23  
24  
25  
26 **Competing Interests:** SMR reports grant funding from Conquer Cancer/Pfizer. VB reports research  
27 funding (paid to institution) from SeaGen, AstraZeneca, Gilead, and Olema; consultation for SeaGen,  
28 AstraZeneca, Lilly, Gilead, and Olema; and stock/founder of PEARL Scientific. AHP reports royalties  
29 from Wolters Kluwer (paid to self) for authorship of UpToDate. All remaining authors have no  
30 disclosures to report.

31  
32  
33  
34  
35  
36  
37 **Author contributions:** AHP, EPW, RMT, and SG conceptualized and developed the cohort and  
38 methodology. LCC provided oversight for pathology review. MEM, CS, and GJK have supported data  
39 and biospecimen collection and management. SG and YZ have provided statistical support. KJR, LS,  
40 JP, SC, VFB, and EW have served as site investigators. AHP, KJR, and PDP provided oversight for  
41 medical record/clinical data review. AHP and SMR provide general oversight and management of the  
42 study. AHP provided funding for the study. AHP is the guarantor of the study. All authors read and  
43 approved the final manuscript.

## REFERENCES

1. Ellington TD, Miller JW, Henley SJ, et al. Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age Among Women Aged  $\geq 20$  Years - United States, 1999-2018. *MMWR Morb Mortal Wkly Rep* 2022;71(2):43-47. doi: 10.15585/mmwr.mm7102a2
2. Miller KD, Fidler-Benaoudia M, Keegan TH, et al. Cancer statistics for adolescents and young adults, 2020. *CA Cancer J Clin* 2020;70(6):443-59. doi: 10.3322/caac.21637
3. Guo F, Kuo Y-f, Shih YCT, et al. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. *Cancer* 2018;124(17):3500-09. doi: <https://doi.org/10.1002/cncr.31638>
4. Kim HJ, Kim S, Freedman RA, Partridge AH. The impact of young age at diagnosis (age  $< 40$  years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. *The Breast* 2022;61:77-83. doi: <https://doi.org/10.1016/j.breast.2021.12.006>
5. Partridge AH, Hughes ME, Ottesen RA, et al. The effect of age on delay in diagnosis and stage of breast cancer. *Oncologist* 2012;17(6):775-82. doi: 10.1634/theoncologist.2011-0469
6. Zabicki K, Colbert JA, Dominguez FJ, et al. Breast cancer diagnosis in women  $\leq 40$  versus 50 to 60 years: increasing size and stage disparity compared with older women over time. *Ann Surg Oncol* 2006;13(8):1072-7. doi: 10.1245/ASO.2006.03.055
7. Azim HA, Jr., Partridge AH. Biology of breast cancer in young women. *Breast Cancer Res* 2014;16(4):427. doi: 10.1186/s13058-014-0427-5
8. Guzman-Arocho YD, Rosenberg SM, Garber JE, et al. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. *Br J Cancer* 2022;126(2):302-09. doi: 10.1038/s41416-021-01597-2
9. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. *Breast Cancer Res Treat* 2011;126(2):529-37. doi: 10.1007/s10549-010-1132-4
10. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. *J Clin Oncol* 2003;21(4):602-6. doi: 10.1200/JCO.2003.07.071
11. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. *J Clin Oncol* 2010;28(27):4120-8. doi: 10.1200/JCO.2009.25.9655

12. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of Life, Fertility Concerns, and Behavioral Health Outcomes in Younger Breast Cancer Survivors: A Systematic Review. *J Natl Cancer Inst* 2012 doi: 10.1093/jnci/djr541
13. Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med* 2016;375(8):717-29. doi: 10.1056/NEJMoa1602253
14. Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. *N Engl J Med* 2021;385(25):2336-47. doi: 10.1056/NEJMoa2108873
15. Sparano JA, Gray RJ, Makower DF, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med* 2015;373(21):2005-14. doi: 10.1056/NEJMoa1510764
16. Warner ET, Colditz GA, Palmer JR, et al. Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40? *Breast Cancer Res Treat* 2013;142(1):165-75. doi: 10.1007/s10549-013-2721-9
17. Bertrand KA, Bethea TN, Adams-Campbell LL, et al. Differential Patterns of Risk Factors for Early-Onset Breast Cancer by ER Status in African American Women. *Cancer Epidemiol Biomarkers Prev* 2017;26(2):270-77. doi: 10.1158/1055-9965.EPI-16-0692
18. Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N Engl J Med* 2018;379(2):122-37. doi: 10.1056/NEJMoa1803164
19. Borstelmann NA, Gray TF, Gelber S, et al. Psychosocial issues and quality of life of parenting partners of young women with breast cancer. *Support Care Cancer* 2022 doi: 10.1007/s00520-022-06852-7
20. Borstelmann NA, Rosenberg S, Gelber S, et al. Partners of young breast cancer survivors: a cross-sectional evaluation of psychosocial concerns, coping, and mental health. *J Psychosoc Oncol* 2020;38(6):670-86. doi: 10.1080/07347332.2020.1823546
21. Dominici L, Hu J, Zheng Y, et al. Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. *JAMA Surg* 2021;156(10):e213758. doi: 10.1001/jamasurg.2021.3758
22. Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. *Ann Intern Med* 2013;159(6):373-81. doi: 10.7326/0003-4819-159-6-201309170-00003
23. Walker HE, Rosenberg SM, Stanton AL, et al. Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer. *J Adolesc Young Adult Oncol* 2016;5(1):16-23. doi: 10.1089/jayao.2015.0051

- 1  
2  
3 24. Sella T, Fell GG, Miller PG, et al. Patient perspectives on testing for clonal hematopoiesis of  
4 indeterminate potential. *Blood Adv* 2022;6(24):6151-61. doi:  
5 10.1182/bloodadvances.2022008376  
6  
7  
8 25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic  
9 comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40(5):373-  
10 83. doi: 10.1016/0021-9681(87)90171-8  
11  
12 26. Sangha O, Stucki G, Liang MH, et al. The Self-Administered Comorbidity Questionnaire: a new  
13 method to assess comorbidity for clinical and health services research. *Arthritis Rheum*  
14 2003;49(2):156-63. doi: 10.1002/art.10993  
15  
16  
17 27. Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age  
18 in a large cohort of young women with breast cancer. *Breast Cancer Res Treat*  
19 2012;131(3):1061-6. doi: 10.1007/s10549-011-1872-9  
20  
21  
22 28. Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO 4th International Consensus  
23 Guidelines for Breast Cancer in Young Women (BCY4). *Ann Oncol* 2020;31(6):674-96. doi:  
24 10.1016/j.annonc.2020.03.284  
25  
26  
27 29. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO  
28 Clinical Practice Guideline Update. *J Clin Oncol* 2018;36(19):1994-2001. doi:  
29 10.1200/JCO.2018.78.1914  
30  
31 30. Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation  
32 strategies in young women with breast cancer. *J Clin Oncol* 2014;32(11):1151-6. doi:  
33 10.1200/JCO.2013.52.8877  
34  
35  
36 31. Lee GE, Rosenberg SM, Mayer EL, et al. Contemporary management of breast cancer during  
37 pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer.  
38 *Breast J* 2019;25(6):1104-10. doi: 10.1111/tbj.13431  
39  
40  
41 32. Poorvu PD, Gelber SI, Zheng Y, et al. Pregnancy after breast cancer: Results from a prospective  
42 cohort of young women with breast cancer. *Cancer* 2021;127(7):1021-28. doi:  
43 10.1002/cncr.33342  
44  
45  
46 33. Poorvu PD, Hu J, Zheng Y, et al. Treatment-related amenorrhea in a modern, prospective cohort  
47 study of young women with breast cancer. *NPJ Breast Cancer* 2021;7(1):99. doi:  
48 10.1038/s41523-021-00307-8  
49  
50  
51 34. Sella T, Poorvu PD, Ruddy KJ, et al. Impact of fertility concerns on endocrine therapy decisions in  
52 young breast cancer survivors. *Cancer* 2021;127(16):2888-94. doi: 10.1002/cncr.33596  
53  
54  
55 35. Lewinsohn R, Zheng Y, Rosenberg SM, et al. Fertility Preferences and Practices Among Young  
56 Women With Breast Cancer: Germline Genetic Carriers Versus Noncarriers. *Clin Breast Cancer*  
57 2023;23(3):317-23. doi: 10.1016/j.clbc.2022.12.012  
58  
59  
60



- 1  
2  
3 36. Partridge AH, Niman SM, Ruggeri M, et al. Interrupting Endocrine Therapy to Attempt Pregnancy  
4 after Breast Cancer. *N Engl J Med* 2023;388(18):1645-56. doi: 10.1056/NEJMoa2212856  
5  
6  
7 37. Lambertini M, Ameye L, Hamy AS, et al. Pregnancy After Breast Cancer in Patients With Germline  
8 BRCA Mutations. *J Clin Oncol* 2020;38(26):3012-23. doi: 10.1200/JCO.19.02399  
9  
10 38. Lambertini M, Ceppi M, Hamy AS, et al. Clinical behavior and outcomes of breast cancer in young  
11 women with germline BRCA pathogenic variants. *NPJ Breast Cancer* 2021;7(1):16. doi:  
12 10.1038/s41523-021-00224-w  
13  
14  
15 39. Poorvu PD, Gelber SI, Rosenberg SM, et al. Prognostic Impact of the 21-Gene Recurrence Score  
16 Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-  
17 Negative Breast Cancer. *J Clin Oncol* 2020;38(7):725-33. doi: 10.1200/JCO.19.01959  
18  
19  
20 40. Sella T, Gelber SI, Poorvu PD, et al. Response to neoadjuvant chemotherapy and the 21-gene  
21 Breast Recurrence Score test in young women with estrogen receptor-positive early breast  
22 cancer. *Breast Cancer Res Treat* 2021;186(1):157-65. doi: 10.1007/s10549-020-05989-5  
23  
24 41. Borstelmann NA, Rosenberg SM, Ruddy KJ, et al. Partner support and anxiety in young women  
25 with breast cancer. *Psychooncology* 2015;24(12):1679-85. doi: 10.1002/pon.3780  
26  
27  
28 42. Rosenberg SM, Vaz-Luis I, Gong J, et al. Employment trends in young women following a breast  
29 cancer diagnosis. *Breast Cancer Res Treat* 2019;177(1):207-14. doi: 10.1007/s10549-019-  
30 05293-x  
31  
32  
33 43. Vazquez D, Rosenberg S, Gelber S, et al. Posttraumatic stress in breast cancer survivors  
34 diagnosed at a young age. *Psychooncology* 2020;29(8):1312-20. doi: 10.1002/pon.5438  
35  
36  
37 44. Park EM, Gelber S, Rosenberg SM, et al. Anxiety and Depression in Young Women With  
38 Metastatic Breast Cancer: A Cross-Sectional Study. *Psychosomatics* 2018;59(3):251-58. doi:  
39 10.1016/j.psym.2018.01.007  
40  
41 45. von Hippel C, Rosenberg SM, Austin SB, et al. Identifying distinct trajectories of change in young  
42 breast cancer survivors' sexual functioning. *Psychooncology* 2019;28(5):1033-40. doi:  
43 10.1002/pon.5047  
44  
45  
46 46. Rosenberg SM, Tamimi RM, Gelber S, et al. Treatment-related amenorrhea and sexual functioning  
47 in young breast cancer survivors. *Cancer* 2014;120(15):2264-71. doi: 10.1002/cncr.28738  
48  
49  
50 47. Rosenberg SM, Tamimi RM, Gelber S, et al. Body image in recently diagnosed young women with  
51 early breast cancer. *Psychooncology* 2013;22(8):1849-55. doi: 10.1002/pon.3221  
52  
53 48. Schapira L, Zheng Y, Gelber SI, et al. Trajectories of fear of cancer recurrence in young breast  
54 cancer survivors. *Cancer* 2022;128(2):335-43. doi: 10.1002/cncr.33921  
55  
56  
57  
58  
59  
60

- 1  
2  
3 49. Rosenberg SM, Dominici LS, Gelber S, et al. Association of Breast Cancer Surgery With Quality of  
4 Life and Psychosocial Well-being in Young Breast Cancer Survivors. *JAMA Surg*  
5 2020;155(11):1035-42. doi: 10.1001/jamasurg.2020.3325  
6  
7  
8 50. Kuijter A, Dominici LS, Rosenberg SM, et al. Arm Morbidity After Local Therapy for Young Breast  
9 Cancer Patients. *Ann Surg Oncol* 2021;28(11):6071-82. doi: 10.1245/s10434-021-09947-3  
10  
11 51. Parsons HA, Rhoades J, Reed SC, et al. Sensitive Detection of Minimal Residual Disease in  
12 Patients Treated for Early-Stage Breast Cancer. *Clin Cancer Res* 2020;26(11):2556-64. doi:  
13 10.1158/1078-0432.CCR-19-3005  
14  
15  
16 52. Waks AG, Kim D, Jain E, et al. Somatic and germline genomic alterations in very young women  
17 with breast cancer. *Clin Cancer Res* 2022 doi: 10.1158/1078-0432.CCR-21-2572  
18  
19  
20 53. Rath M, Li Q, Li H, et al. Evaluation of significant genome-wide association studies risk - SNPs in  
21 young breast cancer patients. *PLoS One* 2019;14(5):e0216997. doi:  
22 10.1371/journal.pone.0216997  
23  
24 54. Olsen SN, Wronski A, Castano Z, et al. Loss of RasGAP Tumor Suppressors Underlies the  
25 Aggressive Nature of Luminal B Breast Cancers. *Cancer Discov* 2017;7(2):202-17. doi:  
26 10.1158/2159-8290.CD-16-0520  
27  
28  
29 55. Stover DG, Parsons HA, Ha G, et al. Association of Cell-Free DNA Tumor Fraction and Somatic  
30 Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. *J Clin*  
31 *Oncol* 2018;36(6):543-53. doi: 10.1200/JCO.2017.76.0033  
32  
33  
34 56. Gibson CJ, Fell G, Sella T, et al. Clonal Hematopoiesis in Young Women Treated for Breast  
35 Cancer. *Clin Cancer Res* 2023;29(13):2551-58. doi: 10.1158/1078-0432.CCR-23-0050  
36  
37  
38 57. Goddard ET, Hill RC, Nemkov T, et al. The Rodent Liver Undergoes Weaning-Induced Involution  
39 and Supports Breast Cancer Metastasis. *Cancer Discov* 2017;7(2):177-87. doi: 10.1158/2159-  
40 8290.CD-16-0822  
41  
42 58. Rocca WA, Gazzuola-Rocca L, Smith CY, et al. Accelerated Accumulation of Multimorbidity After  
43 Bilateral Oophorectomy: A Population-Based Cohort Study. *Mayo Clin Proc* 2016;91(11):1577-  
44 89. doi: 10.1016/j.mayocp.2016.08.002  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Figure Legends**  
4  
5  
6

7 **Figure 1. Overview of YWS data and biospecimen collection**  
8

9 YWS, Young Women's Breast Cancer Study  
10  
11  
12

13 **Figure 2. YWS Study Flow Diagram**  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1. Demographic Characteristics**

	N (%)
<b>Age at diagnosis</b>	
<25	25 (2)
25-30	139 (11)
31-35	352 (27)
36-40	780 (60)
<b>Race</b>	
American Indian /Alaska Native	6 (<1)
Asian	88 (7)
Native Hawaiian/Other Pacific Islander	0 (0)
Black or African American	48 (4)
White	1101 (85)
More than one race	16 (1)
Unknown or not reported	38 (3)
<b>Ethnicity</b>	
Hispanic	56 (4)
Non-Hispanic	1045 (81)
Unknown or not reported	196 (15)

**Table 2. Disease/tumor characteristics and BRCA mutation status (N=1297)**


	N (%)
<b>Stage</b>	
0	98 (8)
I	413 (32)
II	525 (41)
III	197 (15)
IV	64 (5)
<b>Bilateral breast cancer</b>	21 (2)
<b>Tumor grade</b>	
1	89 (7)
2	445 (34)
3	752 (58)
Missing/Unknown	11 (0.9)
<b>ER status</b>	
Positive	945 (73)
Negative	351 (27)
Missing/Unknown	1 (<1)
<b>PR status</b>	
Positive	848 (65)
Negative	441 (34)
Missing/Unknown	8 (<1)
<b>HER2 status</b>	
Positive	360 (28)
Negative	880 (68)
Missing/Unknown/Not performed*	57 (4)
<b>Subtype</b>	
Luminal A-like	395 (31)
Luminal B-like	269 (21)
Luminal B/HER2	255 (20)
HER2-enriched (ER-, PR-, HER2+)	105 (8)
Triple negative	210 (16)
Missing/Unknown	63 (5)
<b>BRCA mutation status</b>	
BRCA1+	90 (7)
BRCA2+	54 (4)
Variant of unknown significance	54 (4)
No mutation detected	919 (71)
Not tested or unknown testing status	180 (14)

\*Missing/Unknown subtype includes cases of DCIS for which HER2 was not performed

**Table 3. Summary of Primary Survey Domains and Schedule, Baseline through Year 15**


	Survey Schedule																		
	Baseline	Month					Year												
		6	12	18	24	30	3	4	5	6	7	8	9	10	11	12	13	14	15
<b>Socio-demographics including insurance, finances</b>	X		X		X		X	X	X	X	X	X	X	X	X	X	X	X	X
<b>Medical/ Family History</b>	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
<b>Genetics</b>			X		X		X		X		X		X						
<b>Health-related Activities/Social History</b>	X		X		X		X	X	X	X	X	X	X						
<b>Fertility/Gynecologic</b>	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
<b>Lactation Assessment</b>	X		X		X		X		X		X		X		X		X		X
<b>Contraception</b>									X		X								
<b>QOL/Anxiety/Depression</b>	X	X	X		X		X	X	X		X			X					X
<b>Coping</b>		X		X															
<b>Fear of Recurrence</b>	X		X		X		X	X	X		X			X					X
<b>Menopausal Symptoms</b>	X	X	X		X		X	X	X		X			X					X
<b>Social Support</b>	X		X		X		X	X	X										
<b>Spirituality Assessment</b>	X						X												
<b>Treatment Decisions</b>		X												X					
<b>Medications List</b>	X		X		X		X	X	X	X	X	X	X	X					X
<b>Tamoxifen Adherence</b>						X													
<b>Healthcare Utilization</b>											X								X

Figure 1



peer review only

Figure 2.





1  
2  
3 **SUPPLEMENTAL MATERIAL**  
4  
5

6 **Cohort profile: Helping Ourselves, Helping Others - The Young Women's Breast Cancer Study**  
7 **(YWS): A multi-site prospective cohort study to advance the understanding of breast cancer**  
8 **diagnosed in women aged 40 and younger**  
9

10  
11 **Supplemental Tables: 2**  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Supplemental Table 1. YWS enrollment sites**

Site	State/Country	Number Enrolled
Dana-Farber Cancer Institute/Brigham and Women's Hospital <sup>a</sup>	MA	669
Beth Israel Deaconess Medical Center <sup>a</sup>	MA	50
Cape Cod Hospital <sup>b</sup>	MA	19
Faulkner Hospital <sup>a</sup>	MA	47
Lowell General Hospital <sup>b</sup>	MA	11
Massachusetts General Hospital <sup>a</sup>	MA	256
Mayo Clinic <sup>a</sup>	MN	35
Milford Hospital <sup>b</sup>	MA	1
Newton-Wellesley Hospital <sup>b</sup>	MA	30
North Shore Cancer Center (Salem) <sup>b</sup>	MA	21
South Shore Hospital <sup>b</sup>	MA	9
Sunnybrook Health Sciences <sup>a</sup>	Canada	62
University of Colorado Hospital <sup>a</sup>	CO	92

<sup>a</sup>academic sites <sup>b</sup>community sites

YWS, Young Women's Breast Cancer Study; MA, Massachusetts; MN, Minnesota; CO, Colorado

Supplemental Table 2. YWS Blood Specimens Collected

Number of Collections	Patients (N)	Baseline	1 year	4 year
1 Timepoint	N=71			
	N=137			
	N=23			
2 Timepoints	N=247			
	N=44			
	N=132			
3 Timepoints	N=471			
<b>Total/Timepoint</b>		N=833	N=987	N=670